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ABSTRACT
Heart valve disease affects an average of 2.5% of the population in the United
States. The mitral valve (MV) is the most complex of the heart’s four valves and is most
associated with the disease by exhibiting altered extracellular matrix (ECM) which
translates into stenosis or regurgitation. These diseases are typically degenerative in nature
and can be accelerated by risk factors such as diabetes and hypertension. With diabetes and
hypertension affecting 425 million and 1.39 billion people worldwide, further investigation
into these risk factors is warranted.
This study aims to develop and test an in vitro model of MV disease. Utilizing
tissue engineering methods and a custom bioreactor, the ability to simulate physiological
and pathological conditions can be obtained. A dynamic in vitro method to study the 3D
complexity of the MV and its associated pathologies is lacking. Here we propose a tissueengineered MV and a versatile MV bioreactor as a model for the identification of valvular
component, cell, and matrix modifications that occur in diabetes and hypertension.
First, a dynamic model was established as a resource to study MV pathologies'
mechanisms. Decellularized porcine MV scaffolds showed comparable mechanical
properties to native valves, while preserving crucial ECM components. A custom mounting
apparatus was able to properly secure the tissue-engineered MV in the bioreactor while
maintaining anatomical geometries. The bioreactor showed proper hemodynamic control
of the MV through appropriate coaptation of the leaflets and opening during the cardiac
cycle with tunable heart rate, pressures, and stroke volume.
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MV scaffolds were recellularized by seeding with valvular interstitial cells (VICs),
and valvular endothelial cells (VECs) and conditioned under normal physiological
parameters or hypertensive, diabetic (high glucose), and diabetic/hypertension combined
conditions. We show here that under pathological conditions, VICs and VECs became
activated and showed signs of ECM remodeling with increased MMP activity. To validate
the in vitro model, we also studied MV pathology in a diabetic minipig model where
similar cellular and ECM alterations were observed.
Overall these results show that our dynamic in vitro model utilizing tissueengineered MVs can be used to study the effects of diabetes and hypertension, two major
risk factors that could lead to MV disease, offering opportunities to strengthen knowledge
in MV pathologies and develop targeted treatment options.
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CHAPTER ONE
REVIEW OF LITERATURE
1.1 Anatomy of the Mitral Valve:
1.1.1 Introduction:
The mitral valve is one of four valves within the heart that helps regulates the
unidirectional flow of blood throughout the heart and into the circulatory system. It is
considered an atrioventricular valve because it is located between the atria and ventricle.
The mitral valve is on the left side of the heart between the left atrium and left ventricle
and prevents the regurgitant flow of blood from the left ventricle into the left atria during
systole. During diastole, the cone-shaped mitral valve is open, allowing oxygenated blood
to flow from the left atrium through the mitral valve and fill the left ventricle. The
ventricle then contracts during systole, and the positive pressure causes the mitral valve
to close. This forces the oxygenated blood out of the ventricle through the open aortic
valve and into the body for circulation. The anatomically complex mitral valve relies on
four main components to ensure proper function during the cardiac cycle. The mitral
valve maintains coaptation during systole with the leaflets but would be unable to
maintain this closure without the support from the annulus, chordae tendinae, and
papillary muscles.
1.1.2 Mitral Valve Annulus:
The structure and support of the mitral valve come from the annulus, which is a
thin, nonconductive, fibro-fatty membrane that is divided into anterior and posterior
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portions [1]. The anterior portion is connected with the aortic annulus and is flanked by
the right and left fibrous trigones separated by a rigid span of fibrous tissue, the
intertrigonal region [1]. The posterior annulus is externally related to the musculature of
the LV inflow region and internally to the left atrium, where it merges with the base of

Figure 1.1: Mitral Annular anatomy showing the hyperbolic paraboloid shape [1]
the posterior mitral leaflet [1]. The mitral valve annulus is thought to mimic that of a
hyperbolic paraboloid which is a geometric shape that looks like a saddle with its peaks
located posteriorly and anteriorly while its valleys are located medially and laterally
(Figure 1.1) [1].
The mitral valve annulus is a dynamic structure that constantly changes its shape
during the cardiac cycle due to its proximity and integration with the surrounding
myocardium and the expansion of the aortic root during systole [2]. During the isovolumic
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contraction (pre-ejection), the hinge angle abruptly increases, reaching the steepest
saddle change of 18 degrees at peak left ventricular pressure. During ejection, the hinge
angle does not change and then decreases during the early filling [3]. The mitral valve
annulus reduces in the area and increases the height of the saddle regions located
anteriorly and posteriorly. This is important so that the area that the mitral valve has to
close during systole is smaller and allows a greater coaptation area for the mitral valve
leaflets. After ejection and during diastole, the mitral valve annulus saddle decreases its
hinge to allow the area of the mitral valve orifice to increase. This will allow for the
efficient flow of blood from the atrium into the ventricle through the mitral valve. Using
three-dimensional echocardiographs, it has been shown that in patients with healthy
annuli, the area and perimeter reach a minimum, nonplanarity is most significant, and
projected shape is least circular during mid systole[2, 4]. The atrial view of the mitral valve
goes from a “D” shape to that of a kidney shape during this cycle. The annular
circumference decreases by 25%, reaching its smallest at the beginning of systole [1, 5].
Mitral annulus area was seen to reduce in size from 8.61 cm2 at end-diastole to 7.61 cm2
at end-diastole Rausch et al. [6]. The mitral valve annulus also folds during the cardiac
cycle. This folding action allows for lower stress seen by the mitral valve leaflets.
1.1.3 Mitral Valve Leaflets:
The main feature of the mitral valve responsible for the closure of the open orifice
area to direct flow out the aorta is the mitral valve leaflets. Below in Figure 1.2, we can
see a visible image of the mitral valve leaflets within the heart's left ventricle with the
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anatomy labeled. There is also a cartoon image showing the cross-section of one of the
leaflets and some microstructures found within. The mitral valve leaflets are separated
into two distinct leaflets, similarly to the annulus, and are referred to as the anterior and
posterior leaflets. The lateral and medial commissures separate the leaflets. The anterior

Figure 1.2: A) Anatomy of the mitral valve leaflets. B) Microscopic cross section of mitral
valve leaflet [7]
leaflet is the larger of the two leaflets and covers approximately two-thirds of the mitral
valve orifice. The posterior leaflet is divided into three separate nodes, which help in valve
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coaptation upon closure. It has also been observed that the anterior leaflet is thicker than
the posterior leaflet [7]. Both leaflets' areas combined are twice the size of the mitral
valve orifice area [2, 8]. This oversized surface area of the leaflets allows for full coaptation
during systole and prevents the retrograde flow back into the heart's left atrium. The
mitral valve leaflets are split into three regions: the base, belly, or central region, and the
free edge starting proximal to the annulus, with the base and distal being the free edge.
The base of the mitral valve leaflets is connected to the continuous fibrous annulus. The
anterior leaflet base connects to one-third of the more fibrous region of the annulus. In
contrast, the posterior leaflet connects to the other two-thirds of the more musculature
annulus [2]. The main distinguishing factor between the free edge and the central belly
region is the insertion of chordae tendinae. Numerous chordal insertions are found within
the free edge region, which has been termed the rough zone due to the irregular texture
and thicker appearance. The central belly region, the clear zone, has few chordal insertion
zones, is located between the annulus and the line of coaptation, and is regular in texture
[2].
The mitral valve leaflets are responsible for creating a seal between the left atrium
and left ventricle during systole. During this cycle, a significant amount of force is
distributed throughout the leaflet and its layers. Mitral valve leaflets experience a variety
of forces such as compression, torsion, and stretching with the addition of shear forces
from flowing blood across the surface [9]. These forces experienced by the mitral valve
leaflets are essential in the healthy regulation of the normal valve physiology [9]. Maeda
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et al. stated that without the proper coaptation of the MV leaflets, it might quickly initiate
a pathogenic response that will continue to worsen [9]. It is suggested that 90 N/m peak
tension is comparable to actual physiological stress levels seen by the mitral valve [10].
Mitral valve leaflets exhibit a nonlinear, anisotropic response characteristic of
collagenous tissues, with the circumferential direction being significantly stiffer and less
extensible than the radial directions [2, 7, 11-13]. The stress-strain curve of mitral valve
leaflets exhibits three key regions. The initial “toe” region is a long low linear slope that
shows minimal resistance to forces; it then transitions nonlinearly into a second linear
region with a very high slope that resists further deformation [2, 7, 11]. The observed
quasi-elastic behavior at physiological strain rates would ensure that the mitral valve
returns to its original conformation without any energy loss, possibly maintaining
synchronous behavior with left ventricular function [10].
1.1.4 Mitral Valve Chordae:
The MV chordae tendinae are located both medially and laterally. They connect
to each leaflet's underside and the lateral and medial papillary muscles. The chordae
tendinae are rich in collagen and elastin fibers due to the purpose they serve in helping
the leaflets from prolapsing back into the atrium during systole [14]. The chordae
tendineae are composed of a cylindrical collagen core within an elastin sheath and have
demonstrable viscoelastic properties – their extensibility decreases with increasing strain
rates and varies with chordal size and location [14, 15]. The chordae tendinae can be more
specifically classified based on their respective insertion region to the leaflet: basal
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chordae attaching to the leaflet base; marginal chordae attaching to the leaflet free edge;
and the notably-thicker strut chordae anchoring at the central belly region of the mitral
valve a critical role in maintaining leaflet coaptation along with left ventricle geometry. It

Figure 1.3: Anatomy of Mitral Valve chordae tendinae [17]
has been observed that the presence of the thicker strut chordae, which are absent in the
posterior mitral leaflet, is considered pivotal for preserving the left ventricle geometry
and systolic function [11]. The strut chords were consistently significantly thicker and
longer than the corresponding marginal chords within the same leaflet [11]. Basal
chordae help to provide a constant connection between the papillary muscle and the
annulus, while the marginal chordae help maintain the mitral valve leaflets' flexibility and
coaptation [2, 16]. Figure 1.3 gives a good illustration of the location and insertion of each
type of chordae tendinae. During peak systolic load experienced by the mitral valve
apparatus of 120 mmHg, the chordae are within tension due to the force being applied in
the upward direction by the leaflets and the counter downward force by the papillary
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muscles. The tension in a single-strut chordae is higher than the load carried by any of the
other groups composed of three or four marginal chordae. It represents 29% of the total
load carried by the papillary muscle [17]. The chordal tension for individual chordae
depended on the chordal structure and insertion in the leaflet. The peak systolic strut
chordal tension is 1.00 +/- 0.42 N and anterior leaflet marginal chordal tension of 0.10 +/0.42 N [18].
1.1.5 Mitral Valve Papillary Muscle:
The mitral valve papillary muscles are extensions of the left ventricle wall that
connect to the chordae tendinae of the mitral valve. The papillary muscles are located in
the anterolateral and posteromedial regions of the left ventricle. Forces experienced by
the chordae tendineae are transferred to the papillary muscles during systole [19]. The
function of the papillary muscle is to apply a tension force to the distal end of the chordae
tendinae to provide an opposing force against the upward force caused by the systolic
cycle keeping the leaflets from prolapsing back into the left atrium. When the left
ventricle contracts, the papillary muscles contract as well. This causes the papillary
muscles to shorten in length and begin to pull on the chordae tendinae. The force of the
blood pushing on the ventricle side of the leaflets is counteracted by the force of the
papillary muscles contracting. Joudinaud et al. showed that the papillary muscles are
anatomically and functionally distinct from the left ventricle wall. They function as a shock
absorber that compensates for the geometric changes of the left ventricle wall while
maintaining their tips at a constant distance to their corresponding mitral hemi-annulus
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[20]. The force carried by one papillary muscle at systolic pressure values of 120 mmHg
and 200 mmHg for the flexible annulus configuration was 3.97 and 6.42 N, respectively
[17].
1.1.6 Microstructure:
The mitral valve's extracellular matrix (ECM) differs in each of the four
components with different amounts and orientations. Still, they all consist of the same
fibrous proteins and polysaccharides throughout. The main fibrous proteins found within
the mitral valve are glycoproteins in nature and are collagen and elastin. Collagen and
elastin are the critical mediators in cell-to-matrix and cell-to-cell interactions. The other
key ECM component is the polysaccharide glycosaminoglycans (GAGs). GAGs are typically
seen bound to other proteins within the ECM forming larger molecules deemed
proteoglycans. These serve many functions in the preservation and integrity of many
tissues in the body. GAGs play a crucial role in cell signaling, which helps to modulate a
vast number of biochemical processes. Some of these processes include regulation of cell
growth and proliferation, promotion of cell adhesion, anticoagulation, and wound repair
[21]. The ECM plays a vital role in proper valve function and critical interactions with
valvular cells to maintain homeostasis. Integrin binds the cells and matrix, allowing
communication between the cells and their habitat. The cells can act on critical
mechanical or chemical cues. These cues from the surrounding environment can elicit the
cells to begin remodeling the ECM and degrade and secrete these ECM components or
do a combination of both. This constant communication between the cells and the ECM
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is vital in normal valvular homeostasis in the ever-changing environment of the heart.
This, however, can also be a detrimental downfall and the initial cause of many valvular
pathologies.
1.1.7 Annulus Microstructure:
While providing the shape, the annulus is mainly a transition region from the
surrounding myocardium and aortic annulus. The more fibrous or anterior annulus
transitions from the aortic annulus into the mitral annulus and further into the mitral
valve's leaflets. This region has a large amount of fibrous protein collagen. Collagen is
known for its high tensile strength in tissues. This key feature is essential in the mitral
valve due to the large forces and deformation experienced through the cardiac cycle.
Along with collagen, elastic fibers are presently dispersed within and around the collagen.
Elastic fibers contain the protein elastin, which has vital properties which mediate tissue
recoil. Tissue recoil is essential in the mitral valve annulus to allow stretching and
contracting. This allows the valve to open completely for maximum blood flow during
diastolic filling and recovery after contraction during systole. The posterior annulus is
more muscular with the involvement of both collagen and elastin to transition into the
multitiered ECM of the leaflets.
1.1.8 Leaflet Microstructure:
The mitral valve leaflets are comprised of three distinct layers that aid in the
normal function of the valve. Each layer has a different ECM composition that is essential
for proper valve opening and closure. The three main layers starting from the uppermost
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(atrial side) to the bottom (ventricular side) are the atrialis, spongiosa, and ventricularis
[2, 15]. The atrialis comprises collagen and elastin sheets due to this layer experiencing

Figure 1.4: Microscopic cross section of Mitral Valve Leaflet [15]
high frequency, large tensile deformations [15]. This elastin-rich area allows for the recoil
of the leaflet during diastole. The bottom layer, the ventricularis, is also called the fibrosa
layer and comprises dense collagen to resist the strains from the ventricular pressures.
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Movat Pentachrome is an excellent staining technique to visualize all the layers of the
mitral valve, as seen in Figure 1.4.
Collagen is the primary protein that provides the tensile strength needed during
peak systolic forces. The collagen is primarily concentrated in the fibrosa. Collagen
alignment with the circumferential direction renders a much stiffer mechanical response
in the circumferential direction along the collagen fibers as compared to the compliant
response when the leaflet is loaded in the radial direction or against the collagen fibers,
which gives rise to the well-characterized leaflet anisotropy and higher circumferential
tensile stresses [11]. The final layer or the middle spongiosa layer is comprised of
proteoglycans and GAGs. GAGs are long negatively charged polysaccharides consisting of
disaccharide units [22]. GAGs and PGs serve their primary function within the spongiosa
layer of the mitral valve leaflets. The PGs are present in the spongiosa and are responsible
for absorbing compressive forces and mediating the collagen and elastin functions. In
contrast, the GAGs are found throughout the leaflet while incredibly dense in the
spongiosa. They are highly hydrophilic, allowing reduced shear between the fibrosa and
ventricularis layers [23]. The PGs and GAGs have been studied in vitro through extraction
and isolation from cartilage with critical observations that the PGs and GAGs exhibit
viscous flow-like characteristics, shear-thinning behaviors, and non-Newtonian fluid
behaviors, demonstrating the constituent as being sensitive to loading rate [23]. It was
found that GAGs are essential to the proper function of the atrioventricular heart valve
leaflets. A GAG deficiency in those leaflets can significantly increase tissue extensibility,
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leading to inadvertent effects such as valvular heart disease [23]. The hydrophilic nature
of these ECM proteins allows for fluid absorption. This absorbed fluid is resistant to
compressive forces that the elastin and collagen fibers cannot prevent. They also recruit
neighboring collagen fibers to provide mechanical stability in fiber-aligned and nonaligned directions.
1.1.9 Chordal Microstructure:
The chordae tendinae attach to the ventricular side of the mitral valve leaflets
insertion zone and are a continuation of the ECM of the ventricularis of the leaflets. They
contain collagen and elastic fibers; however, they are arranged differently than the mitral
valve leaflets. The chordae tendinae have a cylindrical collagen core wrapped in an elastin
sheet [15, 24, 25]. The dense core of collagen allows for resistance to the high tensile
loads brought on by the mitral valve leaflets and papillary muscles, while the elastic sheet
allows for the recoil of the chordae [26].
1.1.10 Papillary Microstructure:
The papillary muscles are extensions of the left ventricle myocardium. They are
comprised mostly of myocardium with collagen and elastin branching into them from the
insertion of the chordae tendinae at the insertion regions.
1.2 Mitral Valve Cells:
The mitral valve is composed of two main cell types. The surface of the valve is
covered by valvular endothelial cells (VECs). It is the continuation of the endothelial cells
from the endocardial endothelial cells of the left atria and ventricle. Found throughout
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the valve components and all layers of the valve leaflets are valvular interstitial cells
(VICs). These cell types are known to actively regulate the normal valve homeostasis [2729]. A disruption in the normal physiology surrounding these cells can result in the
pathological remodeling of the mitral valve. These cells communicate through mechanical
cues and paracrine signaling that cause activation or a phenotypic change of the cells into
one that causes valvular disease.
1.2.1 Valvular Interstitial Cells:
The primary cell type within the mitral valve are VICs. These cells morphologically
have similarities to both fibroblast and smooth muscle cells. While in culture, they
resemble a more fibroblast morphology, in vivo, they show an incomplete basal lamina
which fibroblasts do not, and smooth muscle cells do [30-32]. VICs are responsible for
maintaining normal valve homeostasis by secreting and degrading extracellular matrix
components such as collagen, elastin, and proteoglycans. These cells are believed to be
heterogeneous depending on location within the valve layers [33]. This heterogeneity is
due to the phenotypic change of these cells in response to stimuli. The response to these
stimuli allows the valve to maintain its structural integrity and respond appropriately to
injury. This is key since heart valves are constantly being stressed under the cyclic beating
of the heart to supply the body with constant circulation. However, this important
mechanism of responding to injury and stimuli to maintain a functional valve also causes
pathological diseases of the mitral valve.
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Figure 1.5: Valvular Interstitial Cell phenotypes [15]
It has been discovered that mitral valve VICs can exist in 5 phenotypes [28, 34],
and all five phenotypes are depicted in Figure 1.5. All phenotypes function for a particular
purpose during the mitral valve's development, homeostasis, repair, and pathological
response. The five phenotypes are embryonic progenitor endothelial/mesenchymal cells,
quiescent VICs (qVICs), progenitor VICs (pVICs), activated or myofibroblast-like VICs
(aVICs), and osteoblastic VICs (obVICs). Mitral valve VICs can differentiate into each one
of these phenotypes and can go back and forth between qVICs and aVICs. The ability to
do this is a crucial aspect of mitral valve VICs because it allows for repair when needed.
VICs take on the phenotype of embryonic progenitor endothelial/ mesenchymal
cells in the embryonic development of valve tissues. This phenotype is thought to be the
originator of VICs within the mitral valve tissue, as shown by the above figure. In early
fetal development, the endothelial cells that line the endocardial cushion undergo a
process known as endothelial to mesenchymal transition or EMT. Single endothelial cells
separate from the endothelial and migrate down into the “cardiac jelly” of the
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endocardial cushion [28, 35]. The newly migrated cells undergo a phenotypic change into
VICs, and proliferation and matrix remodeling lead to the development of the heart valve.
In response to injury, the VIC population increases through increased proliferation
and a decrease in apoptosis to allow for proper remodeling of the injury site. However, it
has recently been discovered that this increase in the VIC population may be stemming
from external sources as well [28, 36-39]. Valvular stem cells are not well defined but are
believed to originate from several different origins and appear at the injury site to assist
with the remodeling process. These stem cells are referred to as progenitor VICs (pVICs)
derived from bone marrow-derived cells, circulating cells, and resident pVICs. These cells
are believed to be recruited to the site of injury through specific markers or molecules
that draw them in through adhesion ligands, possibly from precursor cells already in
circulation or from the stem cells in the bone marrow [28, 40, 41]. There is still little known
about pVICs, and further investigations on the origin and how they are
recruited/differentiated at the injury site still need to be explored.
The prominent phenotype of VIC in the mitral valve present during normal healthy
tissue are quiescent VICs (qVICs). These VICs are responsible for maintaining physiological
valve structure and function [28, 30, 33, 42-44]. Known as quiescent, these cells still
regulate matrix synthesis and degradation to maintain normal homeostasis [45].
Resembling fibroblast characteristics and smooth muscle cells, qVICs can differentiate
into most of the phenotypes, as shown in the figure above. To constantly adapt and
maintain homeostasis within the mitral valve, qVICs frequently communicate between
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themselves, mechanical cues from the surrounding matrix, and even valvular endothelial
cells. With the use of two main types of intercellular junctions, VICs maintain the ability
to maintain close contact with neighboring cells [28, 32]. The strong tie cell to cell
adhesion junctions between VIC long processes allows for forming gap junctions between
the cells. These gap junctions, specifically connexin-26 and connexin-45, allow for
constant communication with neighboring VICs [28, 30, 32]. Along with important contact
with these intercellular junctions, these structures could be used as a functional aspect of
mitral valve leaflets, as seen by a decrease in the structural integrity of decellularized
mitral valves. This shows the critical importance of these qVICs within the mitral valve
apparatus during normal healthy function.
The pathological phenotype most associated with calcification of the mitral valve
is osteoblastic VICs (obVICs). Pathological valves have been excised, and studies have
shown that cartilaginous nodules and mature bone, along with proteins associated with
bone formation such as alkaline phosphatase and bone morphogenetic protein (BMP) 2
and 4, are expressed in these tissue [28, 46-49]. VICs in traditional culture do not produce
calcified nodules; however, with the addition of culture media with organic phosphates,
they begin to express chondrogenic and osteogenic markers and form calcific nodules [28,
50, 51]. Through a process similar to atherosclerosis, oxidized cholesterols stimulate VICs

within valvular tissue along with other growth factors to transition into obVICs [52, 53].
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The oxidized lipid nodules lead to activation of VICs in the presence of BMP and TGF-B
and lead to apoptotic alkaline phosphatase enriched nodules that later calcify [54-56].
In response to injury and disease, VICs become activated and become the
activated VIC (aVICs) phenotype. These cells resemble more of a myofibroblast phenotype
and show an increase in several properties, such as an increase in contractility, prominent

Figure 1.6: Activated Valvular Interstitial Cell Pathways [28]
stress fibers, and other contractile proteins [57]. As seen in Figure 1.6, VICs have the
plasticity to go back and forth between qVICs and aVICs in response to injury. This
response allows matrix remodeling and cellular proliferation to be more prominent than
normal tissue homeostasis. The influx of chemokines and growth factors causes the
activation of VICs. It leads to an increase in matrix secretion and degradation with the
expression of matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs),
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along with increased proliferation and migration of VICs [28, 58]. These critical features
of aVICs are all known essential parts of the would repair process. The importance of
cellular activation in response to injury is vital when the injury is fixed, and the cells either
return to qVICs or are eliminated through apoptosis [59]. However, when there is a
dysregulation of any of these processes, aVICs remain, and a cascade effect leads to
pathological fibrosis, angiogenesis, calcification, and chronic inflammation [54, 59]. These
will eventually lead to MV diseases that ultimately need repair or replacement.
1.2.2 Valvular Endothelial Cells:
Throughout the body's circulatory system are a specific cell type that lines all
blood-contacting surfaces. They prevent the thrombosis of blood while allowing nutrients
and other necessary cells and cytokines to pass through. Endothelial cells are essential to
mitral valve development and normal valve homeostasis. As discussed earlier with the
embryonic progenitor endothelial/ mesenchymal cell phenotype of VICs, endothelial cells
mark the beginning of valve development through a process known as endothelial to
mesenchymal transition. Endothelial cells lining the endocardial cushion begin to
transition into VICs through signaling pathways and then migrate inward, forming the
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Figure 1.7: Mitral Valve Development [15]
mitral valve. Through a process of downregulating cellular adhesion molecules while
upregulating contractile proteins such as alpha-smooth muscle actin, VECs begin to
migrate into the valve and become VICs [60, 61]. It has been shown that most cells within
the mature valve are derived from the endothelial cells lining the endocardial cushion [60,
62]. In Figure 1.7, the development of mitral valve leaflets can be observed through the
development of that endocardial cushion and the process of EMT.
Along with being strongly involved in the embryonic development of the mitral
valve, VECs are crucially important in the normal valve homeostasis. The mitral valve
experiences thousands of cycles throughout its life and must adapt to the ever-changing
mechanical forces acting upon them to maintain valve integrity and function [63, 64].
VECs can do this through several different methods, including cellular transformation,
mechanotransduction, and cellular interactions with neighboring VICs [27, 29, 65-69]. It
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was previously discussed how VECs could undergo cellular transformation through
endothelial to mesenchymal transition in response to injury and the need for repair. VECs
can also assist in homeostasis by relaying information to the surrounding environment
through a process known as mechanotransduction. This process allows cells to sense
surrounding mechanical stimuli and convert that into biochemical signals. These signals
will ultimately result in a variety of responses from the cells and activation of cellular
pathways. VECs are constantly being stimulated by several different mechanical forces
such as shear, tensile, and compressive forces [27, 29, 70]. During mitral valve inflow,
peak shear stresses can reach as high as 100 dyn cm-2 with a Reynolds number of around
2053 [71-73], while peak stain levels reach 2.5-3.3% in the circumferential direction and
16-22% in the radial direction [27, 74, 75]. Deviations in these physiological forces are
sensed by VECs and can lead to endothelial dysfunction.
VECs constantly communicate with VICs within the mitral valve and help maintain
a functioning valve. With paracrine signaling, VECs can prevent the differentiation of VICs
into activated and osteoblastic phenotypes [66-69]. One particular signaling molecule
endothelial cells produce is nitric oxide (NO). NO is produced by endothelial nitric oxide
synthase complex. The proactive effect of NO produced by the nitric oxide synthase is
vast and includes regulating vascular tone, leukocyte adhesion to endothelial cells,
cellular proliferation, platelet aggregation, bone mass and turnover, renal consumption
of oxygen, and angiogenesis [76] and can be seen in Figure 1.8 below. These benefits of
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NO production are imperative to proper vascular integrity and function. Many things can
result in the imbalance of eNOS and the bioavailability of NO. Hypertension,

Figure 1.8: The function of eNOS and NO [76]
hypercholesterolemia, atherosclerosis, diabetes, and heart failure have all been linked to
endothelial dysfunction and an imbalance in eNOS function [76].
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1.3 Pathologies of the Mitral Valve:
Heart valves play a crucial role in the proper function of the cardiovascular system.
When there is a disturbance to one of the four valves through disease and pathologies, it
results in decreased quality of life and eventually heart failure in patients with heart valve
disease (HVD). HVD is a significant cause of cardiovascular morbidity and mortalities,
affecting more than 1 in 50 people in industrialized and developing countries [77, 78]. The
prevalence and type of VHD vary around the globe depending on location and economic
status. Rheumatic heart disease (RHD) is still among the most common VHDs worldwide.
Approximately 41 million people are affected by this condition; however, its prevalence
is seen mainly in developing countries [79]. The next leading VHD is degenerative mitral
valve disease (DMVD) which affects more than 24 million people worldwide [79]. With
the MV being one of the most complex of the heart’s four valves, it is also the most
commonly associated with disease [80] due to its multitude of components and the
mechanical demands it must face through each cardiac cycle. MVD becomes more
prevalent with age than other heart valves [78]. Pathologies of the MV are either primary
or secondary in nature. Primary pathologies typically involve the degeneration of valvular
components, while secondary pathologies affect the valve indirectly, such as ischemic
mitral valve regurgitation. The main pathologies commonly associated with the MV are
stenosis, regurgitation, and prolapse.
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1.3.1 Mitral Valve Stenosis:
MV stenosis is most commonly seen in developing countries rather than industrial
nations, where it is the least common valvular abnormality seen in [78]. This is mainly
because MV stenosis has very few causes. While calcification can result in a stenotic valve,
the most common cause is due to a bacteria known as streptococcus pyogenes. When left
untreated, this bacteria will eventually lead to rheumatic fever and, ultimately, rheumatic

Figure 1.9: Excised Mitral Valve showing stenotic lesions. Yellow arrows point to
fused commissures, black arrows to calcium deposits, and an asterisk indicating
shortened and thickened chordae tendinae [81]
heart disease (RHD). RHD is a fibroinflammatory process directly affecting the mitral valve
[81].
Stenotic MV has distinct pathological characteristics, especially those affected by
RHD. These valves tend to have fibrous thickening of the leaflets, fusion of the
commissures, and calcified deposits [81, 82]. These pathological lesions can be seen in
Figure 1.9. All of these result in the narrowing of the MV orifice area substantially. The
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subvalvular components are also affected by RHD. The chordae tendinae become thicker
and fused along with shortened in length. This gives the valve more of a funnel shape with
severe blood restriction due to a decrease in the opening of the valve. With a stenotic
valve, there is a decrease in blood flow during diastole and regurgitation of blood during
systole. The resulting comorbidities are atrial fibrillation and pulmonary hypertension,
resulting in poorly functioning MV. On a microscopic level, stenotic valves show
nonspecific fibrosis, calcification, and myxoid change [81]. There is also an increase in
neovascularization within the leaflets, which is not commonly seen due to increased
inflammation in the area [81, 83]. The resulting neovascularization allows for further
infiltration of inflammatory cells and cytokines, worsening the stenosis of the valve.
1.3.2 Mitral Valve Regurgitation:
Mitral valve regurgitation (MVR) is the most frequent pathology seen within the
MV and is responsible for affecting 10% of the population over 75 years old [84, 85]. The
high prevalence of MVR is due to the multitude of other MV pathologies that result in the
regurgitation of blood into the left atrium during systole. These pathologies include MV
stenosis, annular calcification, MV prolapse, myxomatous degeneration, and many other
valvular diseases. The regurgitated blood that enters the left atrium during ventricular
systole results in a cascade of issues for the patient. The large influx of volume in the left
atrium results in dilation of the atrium and will lead to pulmonary edema and pulmonary
hypertension. If not corrected, these will ultimately lead to heart failure and death. There
are two main routes that MVR can develop and evolve. Functional MVR typically involves
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the remodeling of the left ventricle. This results in anatomical repositioning of key MV
components that leads to the incomplete closure of the MV. The other cause of MVR is
known and primary or organic MVR. Primary MVR results from the degeneration of
valvular components and will lead to regurgitant blood flow. Due to these two types of
MVR being completely different etiologies, the way they are treated is entirely different.
A pathophysiological triad developed by Carpentier enabled a way for a universal

Figure 1.10: Carpentier’s Pathophysiological Triad [86]
assessment of the treatment of this disease [8, 86]. Carpentier’s method, shown in Figure
1.10, was based on the MV leaflet movement and is as follows. Type I is normal leaflet
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movement but includes annular dilation, type II is excessive leaflet movement which
includes MV prolapse, and type III is restricted leaflet motion [86].
Functional MVR can either be ischemic or non-ischemic in nature. Ischemic
functional MVR tends to be prevalent in about 20% of the cases, while non-ischemic can
rise near 86% [87]. These incidences result in alterations to the left ventricle that cause
the MV to become incompetent. Ischemic functional MVR stems from coronary artery
disease that results in myocardial infarctions, while non-ischemic results from the dilated
left ventricle in cardiomyopathy patients [88]. When either happens, the left ventricle
changes geometry and displaces the papillary muscles. While the MV may still be typical
geometry, the displaced papillary muscles cause tethering of the chordae tendinae and
thus apical displacement of the MV leaflets. The combination of these prevents full
coaptation of the leaflets during systole and allows for retrograde blood flow. The
papillary muscles are not the only structure affected and cause functional MVR; the
annulus can also be altered. Due to the dilated left ventricle, the annulus is dilated, mainly
along the posterior, more muscular part of the structure. The annulus increases its
intercommissural diameter from 39 to approximately 42 mm and becomes much flatter
and circular in shape [87]. The now enlarged MV orifice area caused the MV leaflets to try
and compensate for this new larger area that needs to be covered. This tends to happen
towards the leaflet edge and begins immediately as a response to functional MVR,
increasing the leaflet area to approximately 35% of normal valves [87, 89]. However, this
sequence of events is a part of a revolving cycle of worsening functional MVR. As there is
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an increase in MVR, the left ventricle enlarges more, resulting in worsening papillary
muscle displacement, chordal tethering, and a higher degree of functional regurgitation.
Organic MVR is the downstream effect of degeneration of the valvular complex.
One primary degenerative disease seen within the MV is myxomatous mitral valve disease
(MMVD), also known as Barlow disease. With a prevalence of 2.4-5%, MMVD is one of
the most common causes of MVR, especially in elderly patients [81, 90]. MMVD presents
itself as enlarged leaflets, both in length and thickness, dilated annulus, and thicker
elongated chordae tendinae [91]. This is due to the increase in ECM remodeling and
accumulation of proteoglycans. Microscopically, leaflet structure shows drastic changes
and disorganization as MMVD progresses. In the fibrosa of the leaflets, there is a loss of
collagen fibers and fiber orientation, while the spongiosa sees an increase in size with
growing amounts of proteoglycans [91-93]. Through the same response to injury and
repair, VICs are the critical mediators in the pathological remodeling of the MV. In MMVD,
VICs are found to be within their activated state, which means they act like
myofibroblasts. While in this phenotype, they produce large amounts of ECM
components, specifically GAGs and proteoglycans. While in normal circumstances, VICs
would transition back to qVICs after homeostasis was achieved, in MMVD, they remain
activated, resulting in a furious cascade of ECM production and worsening disease. With
more VIC proliferation and aVICs present within the MMVD, there is a much higher level
of enzymatic activity within the leaflet that fuels this pathologic state [94]. There is crucial
importance in the balance between MMPs and TIMPs to maintain proper valve
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homeostasis. In diseased valves, this balance becomes unequal. Specifically in MMVD, an
increase in collagenous and elastin degrading enzymes (MMP-1, MMP-2, MMP-9, and
MMP-13) cause fragmentation of those proteins [15, 94-96]. The fragmentation of
primary structural ECM components (collagen and elastin) reduces the MV's mechanical
properties and overall function. It has been found that in myxomatous leaflets, the
circumferential extensibility increases from 15.5% to 37.2% in healthy and diseased valves
respectively while the radial extensibility increases from 24.1% to 39.7% [97]. The
increase in the extensibility of the leaflets can result in a “flail” leaflet back into the left
atrium of the heart during systole. This flailed section, also called leaflet billowing, is
referenced as MV prolapse (MVP) and will be discussed further in the following section.
MVP is a form of MVR. The mechanically weakened valve leaflets will eventually lead to
improper coaptation and MVR due to the increased enzymatic activity and deposition of
GAGs and proteoglycans. Figure 1.11 shows a cartoon of a normal versus a MMVD valve
leaflet, showing how there is an increase in ECM deposition and thickening of the leaflet.
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Figure 1.11: Normal and MMVD Leaflet Structure [91]
Many things can lead to the activation of VICs into aVICs and further into
myofibroblast in MMVD. These include, but are not limited to, mechanical stress, injury
to the leaflet endothelium, and molecules that are involved in cellular signaling [95]. Two
main pathways that have been shown to play a significant role in the activation of MV
VICs are the 5-HT (serotonin) and transforming growth factor-beta (TGF-b) [98-101]. In
MMVD, these two pathways begin to cross paths and result in one causing an
upregulation in the other. Mechanical stimuli are thought to increase the production of
serotonin and upregulation in the 5-HT pathway. Cell proliferation, collagen synthesis,
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and tissue stiffness in response to this seem to all be mediated by this pathway [102].
TGF-b is upregulated in the presence of increased levels of 5-HT. TGF-b is responsible for
many cellular functions, including cellular differentiation, proliferation, migration, and
apoptosis [91].
The superfamily of transforming growth factors consists of many different
proteins. One that is considered to be involved in the progression of MMVD is a bone
morphogenetic protein (BMP). One particular BMP, BMP4, is highly upregulated in
diseased MV [103]. BMP4 has been shown to be directly linked to the expression of SOX
9, which regulates the chondrocyte-like action of matrix production within the MV [104].
The overproduction of TGF-b and the deteriorating mechanical properties of the MV lead
to the activation of VICs into a myofibroblast phenotype that produces ECM that does not
contribute to the overall mechanical strength of the valve and also proliferates into an
increase in population within the valve. As mentioned earlier, TGF-b also initiates the
transition of endothelial cells into interstitial cells through EMT. This further increases the
presence of interstitial cells and activated cells that promote further pathological
progression.
1.3.3 Mitral Valve Prolapse:
The most common MV disease seen is mitral valve prolapse (MVP), a degenerative
disease in nature. MVP affects 1% to 3% of the adult population in the United States and
more than 144 million people worldwide [105]. Being one of the most common causes of
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MVR, it is also the most common valvular abnormality resulting in surgical repairs [106].
MVP is characterized as the displacement of one or both of the leaflets back into the
atrium during systole. If severe enough, it results in the retrograde blood flow back into
the atrium. Poor cardiac output is the consequence of this. It can contribute to many
other cardiovascular pathologies, such as atrial fibrillation, thrombus formation, and
pulmonary hypertension, leading to heart failure and death if not corrected. MVP is a
form of degenerative valve disease, specifically MVVD, described above.
The degeneration of the valve will lead to valvular insufficiency through the
dilation of the annulus and excessive ECM production, which results in the billowing of
the leaflet or flail as a result of chordal rupture [15]. MVP tends to start as leaflet
billowing, which is designated as the bulging of the leaflet bodies into the atrium. In
contrast, the coaptation point of the leaflet’s free edges remains normal at the ventricular
line. This progresses into prolapse once the coaptation line passes into the left atrium
resulting in moderate to severe mitral valve regurgitation. This process results from one
of two entities, one being MMVD and the other being fibroelastic deficiency (FED). MMVD
also referred to as Barlow’s disease, typically entails enlarged leaflets full of excess
proteoglycans and GAGs, dilated annulus, and elongated chordae frequently engrossed
with calcium deposits. The combination of these morphological changes of the valve and
possible rupture of chordae tendinae leads to the billowing of the leaflets that looks like
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Figure 1.12: Normal versus prolapsed mitral valve [Mayo Clinic 2018]

a “dome” protruding into the left atrium. In Figure 1.12, the leaflet billowing can be seen
to the degree that MVR begins to happen. FED is a less common etiology of MVP but is
characterized as thin leaflets deficient in collagen, elastin, and proteoglycans [107, 108].
The lack of structural ECM components, such as collagen and elastin, results in
mechanically weakened chordae tendinae that tend to rupture. The resulting cause is
improper leaflet coaptation and flailed portions of the free edge of the MV leaflets into
the atrium. Another common cause of MVP results from the improper position of MV
papillary muscles, which puts stress on the chordae and change the geometries of the
valve and, ultimately, the function of the valve. This tends to result as a secondary cause
due to myocardial infarctions and displacement of the papillary muscles either laterally,
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apically, or posteriorly due to the remodeling of the left ventricle after myocardial
infarction [88]. MVP usually goes undetected until it progresses into MVR, requiring
surgical intervention.
1.4 Risk Factors for Mitral Valve Disease:
As mentioned previously, activation of MV cells by either mechanical or
biochemical cues results in the pathological development of MV diseases. Two such risk
factors that have been shown to cause a more rapid progression of MV pathologies,
specifically Mitral Annular Calcification, are Diabetes Mellitus (DM) and hypertension
(HTN) [109]. These modalities lead to the dysfunction of the endothelial layer, infiltration
of inflammatory cells through the increase of adhesion molecules on the endothelium,
and micro-injuries to the subendothelial tissue and ultimately, a common cascade similar
to atherosclerosis seen in arteries [110].
DM is a metabolic disorder affecting more than 425 million people in 2017 and is
expected to reach over 600 million by 2045 [111]. Usually, the body can regulate blood
glucose levels via a feedback loop that releases either insulin to bring down levels or
glucagon to increase levels and maintains homeostasis. When a person is either born with
diabetes (Type 1 Diabetes) and has the destruction of insulin-producing beta cells or
develops diabetes (Type 2 diabetes) through an increase in insulin resistance and
production of insulin, this homeostasis quickly becomes imbalanced. Type 2 Diabetes is
the most common of the two and represents approximately 90% of all diabetics and is
due to the increase in obesity worldwide, specifically in developed countries [111]. The
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diabetic environment has been shown to consist of an excess of blood glucose levels that
lead to the accumulation of glycated ECM that undergo chemical crosslinking leading to
advanced glycosylation end products (AGEs) [112]. These AGEs accumulated along with

Figure 1.13: Reactive Oxygen Species influence on the progression of atherosclerosis
[113]
hyperlipidemia that is associated with DM within the tissue lead to an increase in reactive
oxygen species (ROS) and an increase in oxidative stress felt by the tissue. The
combination of ROS, lipotoxicity, and apoptosis caused by the dysregulated environment
in DM increases the inflammatory response to the area. It leads to a cascade of
differentiation of qVICs to aVICs and ultimately valvular pathologies [113].
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HTN is more prevalent than diabetes and affects an estimated 1.39 billion people
worldwide [114]. A study published in 2017 that followed 5.5 million people for ten years
showed that long-term exposure to HTN was associated with a greater risk of primary and
secondary mitral valve regurgitation [115]. HTN takes the route of inducing mechanical
injury on the valve tissue, leading to an inflammatory/ injury repair response of the native
cells. In a similar mechanism as diabetes, HTN causes vascular inflammation that increases
ROS, endothelial dysfunction, immune activation, and heightened inflammatory
response. As mentioned before, this increases inflammatory cytokines such as interleukin
beta 1 (IL-1b), tumor necrosis factor-alpha (TNF-a), and growth factors such as
transforming growth factor-beta (TGF-b) that all activate signaling pathways that lead to
the activation of valvular cells and initiate pathological remodeling in the valve [116].

Figure 1.14: The role of Diabetes and Hypertension in the progression of
cardiovascular disease [116]
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1.5 Current Solutions:
There is an increasing prevalence of mitral valve insufficiencies, especially in the
elderly population seen throughout the world [79]. If left untreated, the prognosis for
mitral valve disease is very poor, with worsening cardiac output, left ventricular dilation,
myocardial dysfunction, and cardiac failure, which will lead to morbidity and mortality
[117]. This warrants the need for reestablishing proper valve function through surgical
repair or replacement. There is no specific way mitral valve diseases can be corrected,
and every patient entails evaluating and determining the appropriate pathway. Over
300,000 people worldwide, including 44,000 individuals within the United States, undergo
mitral valve surgery for mitral valve diseases each year [118]. Initially, all mitral valve
surgeries were replacement surgeries until crucial people such as Carpentier came along
and made significant advancements in mitral valve repair. Mitral valve repair is still the
gold standard for restoring normal mitral valve shape and function. Most clinicians
recognize that mitral valve repair benefits outweigh replacement in organic mitral
regurgitation [15]. The main question that remains in debate among many is when should
the surgery take place to maintain the stability of the surrounding heart structures [119]
1.5.1 Mitral Valve Replacement:
Mitral valve replacements have been around for several decades, starting in the
1960s with the original ball and cage design that was quickly improved due to problems
that arose from that design [120]. Along with the advancements in both design and
materials of mechanical valves, bioprosthetic valves came around when the discovery of
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the stability of glutaraldehyde tissue came about. This process was used to fix porcine
tissues that provided bioprosthetic valves with much better hemodynamic properties
than the mechanical counterparts [121]. These options, mechanical and bioprosthetic
valves shown in Figure 1.15, are currently being used as viable options for mitral valve
diseases. While there have been many advancements along the way, the general idea
behind each one remains at the core of their existence.

Figure 1.15: Mechanical and bioprosthetic valve replacements [123]

Mechanical valves are more durable because they are made from materials such
as titanium and carbon. Most current designs of mechanical valves consist of a leaflet core
with a metal support ring surrounded by a ring of knitted fabric that is used to sew the
mechanical valve into the place of the old valve [122]. The combination of material and
current designs of the valve replacement are there to reduce fatigue and blood
coagulation compared to the original ball and cage models that are no longer used. The
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main force that these valves experience is at and right after systole, where the
transvalvular pressures are the highest. These loads, along with the thousands of cycles
throughout the valve’s lifetime, produce a tremendous amount of fatigue that is mainly
felt in the hinges of the mechanical valve. The increase in durability comes at a price
because a foreign material is being implanted into the body. Even with the advancements
in materials and biocompatibility of these materials, patients who receive a mechanical
valve still have to take lifelong anticoagulants to prevent thrombus formation, which can
cause stroke or myocardial infarctions due to blood contact with non-endothelial surfaces
[122].
Bioprosthetic valves came to light to solve thrombosis and hemodynamic issues
resulting from mechanical valves. The simple answer was to use a valve that already
existed and mimics the shape of the current valve in the body. When animal tissues were
crosslinked with glutaraldehyde to stabilize and mask antigens that would otherwise
result in an immune response and rejection of the implanted valve, while they are not as
durable as mechanical valves, bioprosthetic valves can last 15 to 20 years and allow the
patient to live without taking lifelong anticoagulant [122]. Initially, these valves would
have some suture ring at the base of the valve and would be surgically sewn into the
patient during an open-heart procedure. With the advancement in minimally invasive
surgery, stent design, and incorporation of valves on these stents, transcatheter heart
valve replacements have become a more common method. Initially only reserved for
high-risk patients, it may one day be the primary method of choice for valve replacements
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[81]. Several factors come into mind to safely implant a prosthetic valve via transcatheter
methods. With the mitral valve having a very complex geometry and critical aspects of
the valve complex integrating with the left ventricle to provide proper function as well as
maintaining a proper and clear left ventricular outflow tract, it makes completing a
transcatheter approach to mitral valve replacement challenging to keep the valve from
migrating and obstructing the left ventricular outflow tract [123].
With these two options of mitral valve replacement, there are many criteria and
considerations that the surgeon must think about before selecting an appropriate valve
for the patient. When looking at mechanical valves, they are preferred when the patient
has no contraindications for anticoagulants, there is a concern for the deterioration of
bioprosthetic in younger patients, and the patient needs the valve to last a long time. On
the other hand, bioprosthetic valves are preferred in older patients who do not have a
life expectancy that would outlast the valve replacement. Additionally, surgeons also have
to consider the lifestyle of their patient in question [124]. For instance, patients with more
active lifestyles or at risk of falling and bleeding do not need to be on anticoagulants due
to severe bleeding. On the other hand, young patients have higher calcification of
bioprosthetic valves due to glutaraldehyde being a promoter of calcium and the fact that
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Figure 1.16: Prosthetic valves explanted after severe dysfunction [124]
calcification is more prevalent in young children [124]. Even with the advancement in
prosthetic valve replacements, there are still many complications that can arise and the
need for secondary replacements down the road, as shown in Figure 1.16. Bioprosthetic
failure is dependent mainly on age, and at year 10 is less than 10% likely to fail for those
over 70 years old but 20% to 30% for patients under 40 [125]. Thromboembolism is a
primary concern with prosthetic valve replacements and is a top cause of morbidity and
mortality in patients, with a prevalence of up to 2.3% per patient-year [126]. These
complications give rise to continued research and innovation in mitral valve replacement
options, especially for the younger population who currently outgrow and outlive
available options and require reoccurring surgeries.
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1.5.2 Mitral Valve Repair:
Mitral valve repair has become the most common and preferred surgical
technique used for MV insufficiencies due to the ability to be effective in restoring normal
valve function and preserving critical anatomical features that support not only the MV
function but left ventricle function as well [86, 127]. It was not until 1971 that the MV
repair as we know it today was introduced by Dr. Alain F. Carpentier [128, 129]. While it
has become increasingly common in developed countries and adopted by many surgeons,
surgical repair of the MV does not outweigh the use of valvular replacement in developing
countries. This is due to the lack of knowledge and training clinicians in developing
countries have access to. The complexity of the MV and diseases associated with the MV
repair techniques is vast. Over the last several decades, improvements have been made
in imaging techniques and understanding valvular pathologies to give us the broad range
of MV repair techniques available to surgeons today.
To successfully repair the MV, there needs to be a complete understanding of
where the dysfunction stems from. This is achieved through extensive pre and
intraoperative imaging and visualization. There are three main goals that MV surgery tries
to accomplish through reconstruction, which include restoring appropriate leaflet
mobility, proper leaflet coaptation, and reconstruction of the MV annulus to a stable state
[86]. Several approaches to surgical repair of MV insufficiencies include percutaneous MV
repair, percutaneous transluminal MV valvuloplasty, minimally invasive MV surgery, and
conventional sternotomy [84]. Due to the advancements in medical devices over the past
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decade, MV repairs can be done via transcatherization and require less post-operative
recovery time while still achieving the same outcome as open MV surgeries. Percutaneous

Figure 1.17: The MitraClip (Abbott Laboratories) and PASCAL (Edwards Life Sciences)
[130]
MV repairs are typically done using the MitraClip developed by Abbott Laboratories and
approved for use in 2008 in Europe and 2013 in the United States [84]. Edwards Life
Science has also introduced a similar device to the MitraClip known as PASCAL. Both of
these devices can be seen in a size comparison and the environment of use in Figure 1.17.
The MitraClip and PASCAL systems use an edge-to-edge repair technique that helps to
alleviate MVR. The device is positioned in an area of flailed leaflets. It uses a clipping
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mechanism to grab a section from the anterior leaflet and one from the posterior leaflet
and bring them together. This creates a “bridge” across both leaflets and reduces the
orifice area opening by creating two separate orifices and preventing the flailed leaflets
from prolapsing back into the left atrium. An annuloplasty is another valve repair
technique that aims to restore the shape and function of the MV annulus. Carpentier, in
1968, developed the first annuloplasty ring that was a complete solid ring; however, it
failed because it introduced high levels of annular and leaflet strains [129]. Since the MV
annulus is a dynamic structure that bends and changes size throughout the cardiac cycle,
a rigid ring was not practical in the long run in restoring proper function. In 1976, Duran
et al. introduced a flexible band that still reduced annular size and allowed for flexibility
of the annulus during the cardiac cycle [129, 130]. Figure 1.18 below shows us the main
types of annuloplasty rings used today. Those are complete or partial rings that come as
rigid, semi-rigid, or flexible, depending on the need of the patient’s valve. The last
structure of the MV that typically undergoes repair to revert insufficiencies is chordae
tendinae. The chordae tendinae of the diseased valves become elongated and lose their
mechanical properties due to the degeneration of the ECM components within the
chordae. These elongated chordae result in MVP and sometimes even rupture. To combat
this issue, Frater and David introduced in the 1980s a technique that involved artificial

44

Figure 1.18: Annuloplasty Rings [129]
chordae or “neochordae” to replace the ruptured or damaged chordae [129, 131, 132].
These polytetrafluoroethylene sutures are used to attach the flailed section of the leaflet
back to the papillary muscle below. The most crucial aspect of chordal replacement is
achieving the proper length to restore proper function. Correcting MVP this way versus
resecting out the flailed segment helps maintain leaflet mobility, and a larger surface area
for coaptation reduces the time spent operating [129].
MV repair techniques remain the gold standard for degenerative valve diseases
and can be done in more than 95% of degenerative valve cases to correct insufficiencies
of the valve [129]. In clinics specializing in MV repair surgeries, patients have very low
operative mortality and greater than 95% freedom from reoperation at 20 years while
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maintaining an average life expectancy [86]. This high percentage cannot be achieved in
developing countries as previously discussed on their degree of training in MV repair
techniques. Unfortunately, with an excellent treatment option, there come limitations.
MV repair works well for degenerative valve diseases but is not as effective for MV
stenosis and MV annular calcification. The timing of MV repair is also essential as it must
be done soon enough so that surrounding structures in the heart are not affected by the

Figure 1.19: Progression of MVR and optimal time for surgery [86]

pathological environment the diseased valve creates [86]. This can be visualized in Figure
1.19 above, showing that after the onset of MVR, there is a critical point in the timeline
that surgery should take place before other pathologies arise, such as pulmonary
hypertension, atrial fibrillation, left ventricle dilation, and left ventricle dysfunction. It is
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not until after left ventricle dysfunction that noticeable symptoms occur for the patient.
MV repair also does not account for the root cause of the pathological modification in MV
disease. While only a temporary fix that can last many years, the valve will continue to
deteriorate and ultimately fail again. While this is not usually seen because repair
surgeries typically occur in later-aged people, and the repairs will outlive their life
expectancy. This comes to be an issue for the younger population that will need future
surgeries down the road to repair an ever-failing valve.
1.6 Tissue Engineered Mitral Valves:
MV insufficiencies are becoming an increasing problem clinicians face today, and
current treatment options often lack the patient’s needs. Replacement valves are prone
to failure and thromboembolism. At the same time, MV repair techniques do not correct
the underlying cause of the diseased valve and will eventually lead to future surgeries.
This is also the case for pediatric patients who will outgrow any current options. In recent
years, much research has been placed on tissue engineering valve alternatives that can
integrate and grow with the patient creating a “living” valve solution [77]. The ideal tissueengineered heart valve would be biocompatible, non-immunogenic, non-thrombotic,
have comparable mechanical properties to native valves, and provide appropriate
adhesion sites for cells [77, 133].
The foundation of tissue engineering depends on three main areas that work
together to create functioning tissues. Those areas include the scaffold, cells, and external
stimuli [134]. The different combinations of each of these can be seen in Figure 1.20
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below. Scaffolds for tissue engineering are meant to be a temporary structure. After
implantation, cells will degrade these scaffolds, and native ECM will be deposited, forming
a new host tissue from the tissue-engineered scaffold. There are two directions that
tissue-engineered scaffolds can take. These include decellularized ECM and synthetic
biodegradable materials. Decellularized heart valves can be allografts or xenografts and
allow for bioactive ligands that support cellular adhesion and maintain mechanical
properties similar to the native tissue [77]. Using detergent and enzymatic methods, all
original cellular and antigenic material are removed from the scaffold, making it viable to
implant without the worry of inflammatory response from the host. One daunting and
unknown factor for decellularized xenografts is the presence of a-gal epitope, which
would cause a hyper-acute host immune response. Many decellularization methods have
been able to denature the a-gal epitope. Still, those methods remove the bioactivity of
the ligands that make these scaffolds favorable for the recellularization [135, 136]. The
other direction is to use synthetic scaffolds that are molded or 3D printed into the desired
valve shape. These can be derived from natural materials such as collagen, gelatin,
hyaluronate, glycosaminoglycan, chitosan, alginate, silk, fibrin, dextran, and Matrigel, or
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Figure 1.20: Tissue engineering paradigm [134]
they can be synthesized from polymers that include polyglycolic acid (PGA), polylactic
acid, polylactic-co-glycolic acid, polyacrylic, and many others [134, 137]. Heart valve
scaffolds can be made from each of these independently or in combination to achieve the
desired biocompatibility, mechanical properties, and biodegradation.
The second necessary component of a living tissue-engineered valve is the cells.
The recellularization of these scaffolds can happen in one of two ways. They can either
be recellularized in vitro or in situ. In vitro recellularization involves adding the cells before
implantation to be preconditioned and allowing them to be fully functional before the
implantation [77]. Cells, such as stem cells that are recellularized on the scaffolds, are
believed to dissipate after the first week of implantation, and host cells infiltrate and take
over. The main advantage of having those cells originally there is to reduce the
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inflammatory response and enhance the neotissue formation and overall clinical outcome
[134]. The downside to having cells on the scaffold is that it drastically reduces the shelf
life of these tissue-engineered heart valves because they have living cells. The alternative
is to implant the valve scaffold without any cells and allow it to become recellularized in
situ or while it is in the body. The advantage is that the scaffold has a long time to stay in
storage because there is no concern about keeping cells alive. However, these scaffolds
tend to be weaker in mechanical properties due to the native ECM and crosslinking that
the cells provide are not present. In situ, the longevity of these scaffolds depends on the
infiltration of host cells into the scaffold to maintain structural integrity [77].
1.6.1 Bioreactors:
Bioreactors are critical in the development of functional tissue-engineered valves.
Recellularization and conditioning of these scaffolds are necessary to promote proper
cellular repopulation and function within the valve microstructure. Bioreactors'
mechanical stimuli have helped promote cellular differentiation and further develop the
mechanical properties of the tissue [138]. This allows the constructs to be fully developed
and adequate for the recipient. Without the proper conditioning of the valve, the cells
within would not be conditioned to the physiological mechanical stimuli seen in the heart.
They would ultimately shock the cells and cause them to differentiate into a pathological
form. Not just the cells that benefit from conditioning within a bioreactor, but
mechanically conditioned valves are more stable than decellularized and unconditioned
valves. Along with mechanical stimuli, bioreactors ensure adequate transport of nutrients
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and waste [77, 139]. This is vital for cells within a scaffold because they rely on the
diffusion of nutrients due to the lack of vascularization. Heart valves, specifically the
leaflets, are typically avascular anyways, so bioreactors are ideal for the growth and
development of these scaffolds.
Bioreactors have a wide variety of uses for heart valves and come in various
functions. They can be designed to assess the individual components of the valve and
their response to pathological stimuli. While isolating different mechanical stimuli such

Figure 1.21: Current bioreactor used in our laboratory
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as stretch, flow, and flexure, cellular responses can be identified due to various
mechanical stimuli. To fully design a fully functional tissue-engineered valve, it must be
evaluated at every level to ensure that the cells and scaffold behave the way they are
designed to do [133]. Most stretch systems such as the Flexcell (Flexcell International,
Hillsborough, USA) and those constructed by individual labs such as Ku et al., Merryman
et al., Balachandran et al., and Gupta et al. mainly focus on the conditioning of valvular
cells or leaflets themselves by applying cyclic stretching to deform the cells or leaflets at
the rate and force that they desire. Another method for testing tissue strips of the heart
valve and segments of scaffolds is flexure bioreactors. These allow for the study of specific
segments of the tissue-engineered heart valve or material that has been seeded against
bending mechanics. Englemayer et al. showed that the cyclic flexure increased collagen
production, cellular distribution in the scaffold, and stiffness significantly more than in
static cases [133]. Flow systems are usually the final independent mechanical stimuli
generally utilized in testing tissue-engineered heart valve scaffolds and cells. Flow
systems usually target endothelial cells due to those being the cell type mainly exposed
to shear stresses within the body. Butcher et al. have shown that valvular endothelial cells
aligned perpendicular to the flow direction and that the shear stress appeared to have a
protective effect against calcification [67, 140, 141]. This group also incorporated cocultures of VICs and VECs and showed that VECS appear to regulate interstitial cell
phenotype and that the shear flow enhances this regulation [67].
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While it is imperative to evaluate the individual mechanical cues on tissueengineered valves and their respective cells, the valve needs to be exposed to
physiological conditions in a physiological environment to assess how it will respond in

Figure 1.22: Bioreactor designs [133]
the body entirely. This is especially important with the MV due to the complexity of the
construct and how every individual component has a vital role in the function of the valve.
Entire valve bioreactors that simulate pulsatile flow, as seen by a few examples in Figure
1.22 above, show a variety of approaches to this technique. Overall, they all contain the
exact mechanisms to produce a physiological environment. This includes a driving force
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that pumps the fluid, a reservoir to hold the media, a section that holds and maintains
the valve, a capacitance region to store and release energy every cycle, a resistance
element, and an area for gas exchange to happen [133]. One of the first to develop
compact heart valve bioreactors that can produce both the systolic and diastolic cycles of
the heart was Hoerstrup et al., followed by Dumont et al., Hildebrand et al., Lichtenberg
et al., and many others [133]. These individuals paved the way for more recent groups
who have greatly improved the designs and functions of these bioreactors, such as Sierad
et al. [142]. All have shown this type of bioreactor to increase cell migration into the
scaffold drastically, increase ECM deposition, and increase construct stiffness [143, 144].
The controllability of these bioreactors allows the user to pick and choose different
physiological and pathological environments that they may want to experiment with,
along with chemically altering the culture media to simulate other pathological conditions
such as inflammation and diabetes. This allows for an unlimited amount of combinations
and possibilities that can be explored with whole valve bioreactors and not just for
conditioning valves for implantation but for in vitro evaluation of pathological
modifications on living valves. The possibilities are endless and current research is
scratching the surface in this field.
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CHAPTER TWO
PROJECT MOTIVATION, SPECIFIC AIMS, SIGNIFICANCE
2.1 Introduction and Clinical Relevance:
Heat valve disease is a significant cause of cardiovascular morbidity and mortality
worldwide, affecting more than 1 in 50 people in industrialized and developing countries
[1, 2]. Most valve-related diseases are caused by alterations that directly affect the valve
tissues or the heart, resulting in secondary changes to the valve [1]. The mitral valve is
the most complex of the heart’s four valves and is most commonly associated with
disease [3]. Mitral valve disease affects 2.4% of the population and is a common
congenital heart defect [4, 5]. The most common pathologies associated with the MV are
mitral regurgitation, mitral stenosis, myxomatous degeneration, and MV prolapse [4]. In
industrialized nations, MV prolapse is the most common cardiac valvular abnormality
seen [6, 7]. MV prolapse may not cause mortality but can lead to heart failure, with
complications that include arrhythmia, endocarditis, and sudden cardiac death [8-10].
Degenerative diseases of the MV are the most prevalent reason the valve becomes
diseased. Myxomatous MV disease is currently the most common cause of pure mitral
regurgitation in western countries [11]. This is usually due to the mitral valve leaflets
increasing in size due to mechanoconditioning of the leaflets that reshape due to other
pathological conditions such as hypertension. The increased pathological pressures and
shear due to inadequate blood flow within the heart will activate valvular cells. These
activated valvular cells will begin remodeling the extracellular matrix components within
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the valve to combat the changes in mechanical cues. Mitral valve disease has been linked
to various mechanoactive genes, such as extracellular components, mechanotransductive
elements, and transcription factors. Mechanical stimulus in the microenvironment
provides inductive signals of homeostasis and remodeling to the native cells [4]. The
mitral valve relies on a precise arrangement of extracellular matrix (ECM) components
and cellular activation to maintain normal shape and function. It is comprised of two cell
types and several critical extracellular matrix components. The ECM can transmit external
mechanical stimuli, such as stretch, shear stress, and pressure, to the cell via integrins and
other membrane-bound protein receptors [12]. The two cell types mainly occupying the
mitral valve structures are surface-laden valvular endothelial cells (VECs) and subsurface
valvular interstitial cells (VICs). VICs in diseased valves are primarily in an activated
myofibroblast-like phenotype characterized by expression of vimentin and smooth
muscle a-actin [9].
The normal function of the MV is dictated by the structural interplay of the
individual components synergistically opposing the left ventricular pressure forces. This
includes: mitral annular contraction and bending, apical-basal motion and membrane
deformation of the leaflets, restraining tensile chordal forces, and the tension generated
by the contracting papillary muscles [13]. Several clinical solutions to MV diseases range
from minimally invasive to total valve replacements. It has been found that mitral valve
repair is the preferred method due to an improved long-term survival [14]. With the
complexity of the MV playing a critical role in both the function of the valve and left
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ventricle, it is preferred to keep this intact with repair due to the replacement being linked
to a decrease in the left ventricle function [14]. Typical surgical repairs include
annuloplasty, leaflet remodeling, and chordal repositioning or replacements. These
methods help restore proper valve geometry and, ultimately, valve function. Two types
of valves are used for replacement surgeries: mechanical and chemically fixed xenogeneic
valves. While both replacements serve as viable solutions to mitral valve insufficiencies,
they have several downsides. Mechanical heart valves, made of plastic or metal, can elicit
thrombogenic responses and result in the patient having to be on lifelong anticoagulants
[1]. On the other hand, bioprosthetic valves tend to calcify in younger patients and, due
to their devitalized states, are less durable than native valves because they lack the living
cells to self-repair under the repetitive forces in the valve environment [1]. With both
options having a limited lifespan, the eventual need for an additional replacement, and
the inability to grow and adapt in pediatric patients, there is a need for a better
understanding of mitral valve pathologies to explore options to prevent the need for
mitral valve replacement. With the development of a mitral valve prolapse model through
these proposed aims, macro and microscopic evaluation of mitral valve pathologies can
be further explored using a tissue engineering approach utilizing the entire mitral valve
apparatus as it would be in the body.
Our goal is to study the macro and microscopic alterations of tissue-engineered
MVs under diabetic, hypertensive, and combined diabetic and hypertensive conditions,
risk factors that could lead to MVD. We propose to use a tissue-engineered MV and a

67

versatile MV bioreactor as a model for the identification of valvular component, cell, and
matrix modifications that occur in diabetes, hypertension, and the combination of
hypertension and diabetic conditions. Here we hypothesize that simulated risk factors
will cause cellular and extracellular alterations to the MV that mimic the alterations seen
in MVD. Upon completion, this model can serve as a foundation for further in vitro
investigations of MV disease.
2.2 Specific Aims
Three interrelated and overlying aims were developed to achieve the overall goal
of this research. These aims are directed toward developing an in vitro model that can
explore pathological modifications within the mitral valve by utilizing a tissue-engineered
approach and versatile bioreactors under normal and pathological conditions.
Aim 1 (Chapter 3): Develop a viable tissue-engineered MV model with bioreactor
conditioning
Hypothesis: MV tissue engineering approaches utilizing scaffolds, cells, and
bioreactors can serve as a reliable in vitro model for studying MV biology and pathology.
Approach: A detergent-based decellularization method will remove all cellular
materials from a porcine MV and maintain structure and mechanics. MV interstitial and
endothelial cells will be isolated from fresh porcine MV leaflets and cultured for scaffold
recellularization. The previously developed bioreactor will be optimized to support the
MV function and mounting apparatus properly. We will validate the scaffolds' complete
cellular and DNA removal and then mount them within the optimized mounting device
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within the bioreactor and determine the proper function of the valve under a
physiological environment.
Innovation: While there have been multiple reports of analysis on diseased MV,
most of these stem from late stages of the disease with a heavily deteriorated MV
construct and represent just a snapshot in time. On the other hand, most in vitro models
look at individual components of the valve itself in cell culture. Our approach aims to
develop an entire MV model that evaluates all four structures of the complex valve in
unison. This model will give an appropriate scaffold and conditioning environment that
can be manipulated in various ways to study the entire MV construct in its complete
functioning form. In addition, the use of the MV bioreactor adds the dynamic, pulsatile
element that is lacking in simple cell culture experiments.
Aim 2 (Chapter 4): Determine the effects of high glucose and high blood pressure on
tissue-engineered MVs
Hypothesis: With the addition of diabetes, hypertension, and the combination of
both risk factors during bioreactor conditioning of tissue-engineered MV, we will identify
pathological cellular activation and molecular alterations.
Approach: MV scaffolds will be recellularized by seeding with VICs interstitially
and VECs externally and then conditioned within the bioreactor. The valves will remain in
the bioreactor for one week total with a 3-day ramp-up at the beginning to slowly
introduce mechanical stimuli to the valves. Different conditions will be added, such as
high glucose media, hypertensive pressures, and a combination of both. Valves will then
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be removed from the bioreactor and analyzed for cellular viability, mechanical properties,
ECM alterations, and protein analysis.
Innovation: Diabetes and hypertension have been linked as comorbidities of
valvular disease and have been shown to accelerate the progression of MVD. However,
little has been revealed about these risk factors' initiation and progression of MVD. This
study will give early insight into the pathological cellular activation and molecular
alterations resulting from diabetic and hypertensive conditions.
Aim 3 (Chapter 5): Compare the in vitro and in vivo models of MV pathology: the cellular
and molecular alterations associated with MV pathology under diabetic conditions.
Hypothesis: Alterations of MV VICs and VECs, as well as ECM components by
diabetes, can be identified using MV tissue engineering models and diabetic minipig
models.
Approach: MV scaffolds will be recellularized with VICs interstitially and VECs
externally and then conditioned under high glucose conditions for one week in the
bioreactor. Valves will then be collected and analyzed for cellular and ECM modification
using histological and biochemical methods. Diabetic minipigs at 10 months after
induction of diabetes were euthanized, and MVs were collected and analyzed using the
same techniques as the tissue-engineered valves. These two models will be compared for
similarities in cellular and ECM response to diabetic conditions.
Innovation: The results from this experiment will provide two viable models for
diabetic effects on the MV. An in vivo and in vitro approach will give insight into the
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cellular, and ECM modifications brought about by diabetes. With an in vivo model, we can
validate our own in vitro model. Thus, the in vitro approach can study many different
pathologies associated with the MV and further advance our knowledge of the disease
progression and the influence risk factors have on MVD.
2.3 Significance:
With a lack of in vitro models to study the MV and its associated pathologies, this
research will be aimed at filling the knowledge gap and providing an adequate model
that can be utilized to study MV disease. By developing a tissue-engineered MV and
using a versatile MV bioreactor, the outcome of our studies could lead to an insightful
understanding of how the alterations of MV components under diabetic and high blood
pressure conditions could lead to dysfunctional remodeling and MVD.
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CHAPTER THREE
DEVELOP A VIABLE TISSUE-ENGINEERED MV MODEL WITH BIOREACTOR
CONDITIONING
3.1 Introduction:
There have been multiple reports of analysis on diseased MV; most of these stem
from late stages of the disease with a heavily deteriorated MV construct. On the other
hand, most in vitro models look at individual components of the valve itself. An in vitro
model of the MV that can be used to study pathological mechanisms is warranted. We
are proposing here a tissue-engineered approach, using valve scaffolds, cells, and
bioreactor conditioning. The ideal TEHV should be biocompatible, non-immunogenic,
non-thrombotic, have comparable mechanical properties to native tissue, and provide
appropriate adhesion sites for cells to populate the material and transform it into a living
structure [1, 2]. There are two main methods to develop a TEHV: decellularized and
synthetic scaffolds. Synthetic scaffolds typically lack the mechanical strength of native
valve tissue and would deteriorate before cellular deposition and formation of native ECM
structures [2, 3]. A more promising direction is with decellularized scaffolds that contain
bioactive ligands that can support cellular adhesion and their mechanical properties
remain similar to native tissues [2]. Decellularizing the whole mitral valve apparatus
allows for all components, annulus, chordae tendinae, leaflets, and papillary muscles, to
remain intact. Once a scaffold has been developed, recellularization and conditioning of
these scaffolds are necessary to promote proper cellular repopulation and function within
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the valve microstructure. In tissue-engineered valve constructs, mechanical stimulation
promotes cell differentiation and the development of tissue mechanical properties [4-9].
Bioreactors are commonly used to provide this mechanical stimulation in an in vitro
setting. Bioreactors can provide controlled mechanical stimuli in an environment of
physiologic pressures, flow and temperature that closely mimics the heart. They can also
ensure adequate transport of nutrients and waste and apply dynamic forces to the tissue
necessary for proper tissue maturation, as dynamically cultured valves display deeper cell
penetration and improved mechanical properties [2, 4]. This aim will use the combination
of viable scaffolds and functional bioreactors to create a dynamic model that can be used
for further investigations.
3.2 Materials and Methods:
3.2.1 Mitral Valve Scaffold Preparation:
Porcine mitral valves were collected from a local abattoir and transported on ice
to the lab. After cleaning and trimming any extraneous heart muscle, the valves were
immersed in ddH2O overnight at four °C to induce hypotonic shock and cell lysis. The next
day, the valves were treated with NaOH 0.05M for 2hrs, then incubated for 5 days, under
agitation, in a solution containing 0.2% sodium dodecyl sulphate (SDS), 1% Triton X100,
1% deoxycholic acid, 0.4% EDTA, prepared in 20mM TRIS pH 7.4. To remove the
detergents, the valves were rinsed ten times 15 minutes with fresh ddH2O, then treated
with 70% ethanol for 20 minutes to reduce the bio-burden and extract residual SDS, and
rinsed four times 15 minutes again with ddH2O. Nucleic acid removal was completed by
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incubating a 720 mU/mL deoxyribonuclease and 720 mU/mL ribonuclease for two days
at 37°C. Finally, scaffolds were rinsed in ddH2O (3 times for 15 minutes) and incubated in
0.1% sterile peracetic acid in PBS pH 7.4 for 2 hours. Valves were rinsed twice in sterile
PBS for 30 mins and then an overnight incubation in sterile PBS. Valves were then stored
in sterile PBS in the fridge at four °C until use.
3.2.2 Cellular Isolation and Culture:
Porcine MV valvular interstitial cells (VICs) and valvular endothelial cells (VECs)
were isolated from fresh porcine MV leaflets using a collagenase/explant method. VICs
and VECs were cultured in cell culture flask with DMEM (Corning), 10% FBS (Atlanta
Biological), and 1% antibiotic/antimycotic (Corning) until 85- 90% confluency. Cells were
passaged using trypsin with EDTA (Corning) until the passage of 4 to 7 was achieved.
3.2.3 Mitral Valve Mounting System:
The MV mounting system was designed to accommodate the average size of the
MV annulus and chordae tendinae and retain the anatomical shape, as described in the
literature [10-17]. These measurements were added to a custom design within a 3D cad
system (SolidWorks) and then printed using a nylon 3D printer.
3.2.4 Bioreactor Modifications:
The previously developed MV bioreactor was modified with an additional acrylic
piece to accommodate the papillary muscle attachment points on the MV mounting
system. Without the addition of this extension chamber, the silicone membrane would
come into contact with the MV mount and could cause membrane failure.
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3.2.5 Mechanical Testing:
The biaxial protocol was previously reported [18]. Biaxial testing assessed the
mechanical properties of MV leaflets (fresh, decellularized, and conditioned; n = 3 per
group). Square samples, approximately 10mm by 10mm, were taken from the clear zone
of the anterior MV leaflet. Pieces were cut and oriented so that one edge of the square
would be aligned in the circumferential direction (fiber direction) and another edge would
be aligned in the radial direction (perpendicular to fiber direction). The thickness of each
sample was measured three times using a digital thickness gauge and recorded. Samples
were attached to the Cellscale biaxial machine via stainless steel biorakes. Standard
testing protocols require a 0.1 N/m preload. Each tissue sample was preconditioned with
40 N/m, 60 N/m, and three cycles of 100 N/m. A 10-cycle 100 N/m biaxial test protocol
followed the preconditioning cycles with equiaxial tension. Stress and strain in both the
circumferential and radial directions were calculated from the tissue samples' forcedisplacement data and thickness.
3.2.6 Histology:
Formalin fixed and paraffin-embedded tissue samples were sectioned to 5 um,
rehydrated, and stained with hematoxylin and eosin (H&E) staining for general
extracellular matrix (ECM) compositions and cellular localization. Further ECM
composition and analysis were performed using Masson’s Trichrome combined with
Verhoeff-Van Gieson stain to visualize collagen and elastin within the tissues.
3.2.7 DNA Extraction and Quantification:
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DNA was isolated from tissues following the instructions provided in the DNeasy
Blood & Tissue Kit from Qiagen (Germantown, MD). Concentration was measured using
a NanoDrop 2000, Spectrophotometer, UV-Vis; (Thermo Scientific), and DNA integrity was
determined by ethidium bromide agarose gel electrophoresis using the Sub-Cell GT
electrophoresis instruments and instructions (170-4402) provided by BioRad.
3.2.8 Statistical Analysis:
Results were expressed as Mean ± Standard deviation. Statistical analysis was
performed between groups using Tukey’s student two-tailed T-test in Microsoft Excel.
Statistical significance was determined at a confidence interval of 95% (p<0.05)
3.3 Results:
3.3.1 Mitral Valve Scaffold Development:
Scaffolds were successfully excised from the porcine heart maintaining all four
valvular components. The macroscopic view of the decellularized valves was indicative of
the removal of cellular material through the change from a reddish-brown color to that
becoming lighter and ultimately a snow-white color and slightly translucent (Figure 3.1 A,
C). Through the treatment of alkaline solutions followed by detergents and nucleases,
cellular and nuclear material was removed while maintaining the matrix composition of
the valve.
The removal of cellular and nuclear material was further confirmed through
histological analysis with DNA quantification. Histological evaluation using hematoxylin
and eosin staining protocol showed the complete reduction of all cellular remnants
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(Figure 3.1 B, D). DNA was isolated from fresh and decellularized scaffolds to quantify
using electrophoresis, followed by densitometry. Electrophoresis showed no notable
bands in the decellularized samples (Figure 3.1 E), and densitometry and NanoDrop
showed significantly lower DNA content within the scaffolds with less than 50 ng/mg
(Figure 3.1 F) DNA per milligram dry weight of tissue.
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Figure 3.1: Mitral Valve Scaffold Decellularization. A) Image of a fresh porcine MV within
the heart's left ventricle. B) Microscopic cross-sectional image of a fresh MV leaflet
stained with hematoxylin and eosin showing ECM composition and cellular presence. C)
Macroscopic view of decellularized MV leaflet showing the white color after
decellularization indicating removal of cellular material. D) Microscopic cross-sectional
image of a decellularized MV leaflet stained with hematoxylin and eosin showing no
cellular presence within the scaffold. E) Ethidium Bromide agarose gel electrophoresis
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analysis was used from DNA extracted from fresh and decellularized (Decell) MV
components with a standard ladder. No bands were detected, verifying that there was
complete removal of DNA from the scaffolds. F) Using densitometry, DNA quantification
was looked at between fresh and decellularized MVs. All decellularized components
showed a significant reduction in DNA content, 50 ng/mg ECM weight threshold all fell
below the threshold of 50 ng/mg ECM weight.
3.3.2 Scaffold Structure and Matrix Integrity:
Removing cells and preserving collagen and elastin are crucial for the structure
and integrity of the tissue-engineered valve. Figure 3.2 A, B shows a Masons trichrome
stain combined with VVG to show elastin and collagen fibers. It was found that after the
complete removal of cellular and nuclear components, the native ECM remained intact,
with collagen and elastin remaining in complete fiber forms. The removal of cells and
some glycosaminoglycans allowed for the formation of pores (Figure 3.2 B) between
collagen fibers, which are essential for the repopulation and migration of new cells in the
recellularization process. Biaxial testing showed a loss in the mechanical stability of the
decellularized leaflets (Figure 3.2 C, D, E, F), mainly in the circumferential direction. A
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significant difference was seen from the linear elastic moduli in the circumferential
direction but not the radial (Figure 3.2 E, F).

*
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Figure 3.2: Mitral Valve Scaffold Characterization. A) Microscopic cross-section of a fresh
MV leaflet stained with Trichrome VVG to evaluate collagen and elastin presence
indicated by blue collagen and black elastic fibers. B) Microscopic cross-section of a
decellularized MV leaflet stained with Trichrome VVG to evaluate collagen and elastin
presence indicated by blue collagen and black elastic fibers. C, D) Stress-strain curves for
both fresh and decellularized leaflets in both the circumferential (fiber aligned) and radial
(fiber perpendicular). Y-axis is stress [kPa] and x-axis is strain [% elongation]. E) The
unidirectional elastic modulus was determined from the linear region of the stress-strain
curves. Fresh and decellularized leaflets showed a significant difference in the
circumferential direction*.
3.3.3 Mitral Valve Mounting Apparatus:
After the development of an appropriate scaffold, a mounting mechanism to
support the complex geometry of the MV was necessary. The design was based on a
similar design developed by a previous member of the lab and optimized for better
anatomical positioning and function of the valve. Using literature values, the hyperbolic
paraboloid shape of the annulus was designed in SolidWorks, and a two-piece mounting
apparatus was 3D printed using a nylon-based polymer (Figure 3.2). On the bottom of the
mount is a circular ring with cross members to attach the papillary muscles utilizing
springs equivalent to papillary forces during the cardiac cycle. A 3D printed curved-shaped
papillary support was used to secure the papillary muscles to the mounting apparatus.
Finally, the two-part mounting device was secured with a stainless steel ring and spring
combination to hold tension.
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A2

B1

C

B2

D

Figure 3.3: Mitral Valve Mounting Apparatus. This figure shows all the components for
the mounting of the MV scaffold. A) New mounting frame. B) The two-piece mounting
platform pinches the tissue around the annulus, shaping it into the correct anatomical
shape. C) The papillary muscles are secured to the lower half via springs to the circular
support ring. D) The two halves are held together via a stainless steel and spring mounting
ring.
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3.3.4 Mitral Valve Bioreactor Evaluation:
The bioreactor was optimized by adding an extension chamber to allow the mitral
valve mount to fit without interfering with the silicone diaphragm beneath it (Figure 3.4
A). The hemodynamic assessment of the valve showed proper opening and closing of the
valve with leaflet coaptation (Figure 3.4 B, C). Using ultrasound, further leaflet
hemodynamics were assessed with proper leaflet coaptation during systole with no
noticeable regurgitate jets back into the atrial chamber as shown by the doppler flow
(Figure 3.4 D, E, F). Cellular viability was maintained during the one-week incubation, as
shown by live dead stain analysis (Figure 3.4 G, H).
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Figure 3.4: Mitral Valve Bioreactor. A) Entire MV bioreactor consists of three primary
fluid holding chambers and one air chamber. The MV sits between the atrial and
ventricular chambers. B, C) Top view of the MV within the bioreactor showing the MV
open and closed during systole and diastole, respectively. D) Ultrasound with recorded
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doppler flow showing flow through the valve during diastolic filling and no regurgitant
flow during systole. E, F) Ultrasound images showing a top and cross-sectional view of the
mitral valve in the bioreactor showing proper leaflet coaptation. G, H) Live/Dead stained
images (live, green) from the bioreactor showing cellular viability after the one-week
incubation period.
3.4 Discussion:
3.4.1 Mitral Valve Scaffold Development:
Three things need to come together to develop a fully functioning in vitro model:
a scaffold, cells, and a way to condition the valves. Bioreactors have been utilized to
condition cells and scaffolds over the past decade due to their ability to successfully
promote cellular repopulation and integration within the scaffold ECM and develop a
functional tissue [9]. While there are a few whole valve MV models, most cases are
models utilizing only individual mitral valve components. Examining the MV as a whole
functional unit is imperative because all valve features play a crucial role in the function
of the valve and surrounding tissues.
Decellularization of tissues has been explored in research [19]. Using a detergentbased decellularization method previously established in our lab, the successful removal
of cellular and nuclear material was achieved [20]. After the decellularization process,
excised MVs changed from a reddish-brown color that fresh tissue possess to that of
white and semitranslucent tissue that indicated the removal of cellular material (Figure
3.1 A, C). The histological analysis helped to confirm our removal of cellular material
further. Each image shows the cross-section of the leaflet so that all three layers of the
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leaflet microstructure can be examined and analyzed. Hematoxylin and eosin staining
showed no cellular presence in all decellularized sections compared to fresh tissue (Figure
3.1 B, D). To ensure proper removal of nuclear material, the decellularization protocol
includes an incubation period with DNase/RNase. This enzymatic process helps eliminate
possible DNA and RNA remaining in the scaffolds by hydrolytic cleavage of
phosphodiester linkages in the DNA and RNA backbone. After DNA extraction from fresh
and decellularized scaffold samples, ethidium bromide agarose gel electrophoresis and
densitometry was used to quantify the removal of nuclear material from the scaffolds.
Using ethidium bromide agarose gel electrophoresis, no noticeable bands of DNA were
detected in any decellularized scaffolds (Figure 3.1 E). Using densitometry methods,
quantifiable amounts of DNA were determined in nanograms of DNA per milligram of dry
tissue weight. In all sections of the decellularized scaffold, it was shown that there was a
significant decrease in DNA content compared to that of fresh tissue. Fresh tissue showed
upwards of 500 ng/mg DNA, while decellularized scaffolds showed less than 50 ng/mg
DNA. This is key because Badylak and his group established that completely removing all
DNA from a scaffold would be near impossible. However, if it could be removed to levels
less than 50ng/mg of ECM, it would be acceptable for use and considered decellularized.
Our scaffolds have satisfied these criteria as shown in Figure 3.1 F.
3.4.2 Scaffold Structure and Matrix Integrity:
While removing cellular and nuclear material is the most crucial part of creating a
decellularized scaffold, the scaffold would be invaluable without keeping the matrix intact
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and maintaining the structural integrity. If the decellularization process removed key
matrix components such as collagen and elastin, the scaffold would resemble several
pathological environments such as fibroelastic deficiency (FED). FED is a less common
etiology of MVP but is characterized as thin leaflets deficient in collagen, elastin, and
proteoglycans [21, 22]. The lack of structural ECM components, such as collagen and
elastin, results in mechanically weakened chordae tendinae that tend to rupture.
The decellularization method used for this project successfully maintained
mechanical properties to have a viable scaffold. Histological analysis using a combination
of Mason’s Trichrome and Verhoeff-Van Gieson stain. Mason’s Trichrome helps to
visualize collagen fibers via a vibrant blue color along with muscle and cytoplasmic
material red. With the addition of Verhoeff-Van Gieson, elastic fibers become visible as
thin black fibers. Decellularized sections showed the preservation of both collagen and
elastin (Figure 3.2 B) along with pores left behind by removing cells and secondary ECM
components that will allow for the proper migration of new cells within the valve scaffold.
The mechanical strength of the scaffold was explicitly lost in the circumferential or the
fiber direction (Figure 3.2 C, D, E). This is due to the decellularization method removing
the cells and GAGs from the scaffold. The integrin-binding of the cells to the matrix
provides some mechanical stability under strain conditions. It was found that GAGs are
essential to the proper function of the atrioventricular heart valve leaflets. A GAG
deficiency in those leaflets can significantly increase tissue extensibility, leading to
inadvertent effects such as valvular heart disease [18]. The hydrophilic nature of these
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ECM proteins allows for fluid absorption but also makes GAGs readily extractable during
decellularization. This absorbed fluid is resistant to compressive forces that the elastin
and collagen fibers cannot prevent. They also recruit neighboring collagen fibers to
provide mechanical stability in fiber-aligned and non-aligned directions. Even though the
mechanical strength of the decellularized leaflets was reduced, the linear elastic moduli
were significantly different compared to fresh but only in the radial direction (Figure 3.2
E).
3.4.3 Mitral Valve Mounting Apparatus:
The ability to appropriately mount and secure the MV and all of its components is
essential for the proper function of the valve. The mitral valve annulus is a dynamic
structure that constantly changes its shape during the cardiac cycle due to its proximity
and integration with the surrounding myocardium and the expansion of the aortic root
during systole [23]. Creating a dynamic mount is out of the scope of this research but
capturing the most crucial shape during systole when the forces are the highest and the
stress on the MV components is at its maximum, is important. By reviewing literature
values, average size was used to create commissure to commissure values and anterior
and posterior peak heights (Figure 3.3). Another crucial part of the mounting apparatus
was securement for the papillary muscles and chordae tendinae. Without the proper
securement of these features, there would be no opposing force on the leaflets during
systole, and they would prolapse. In the lower mount, with the approximate size of the
left ventricle in mind, the papillary muscles can be secured and positioned adequately on
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this ring via papillary supports and springs to the double bar and oppose the forces (Figure
3.3).
3.4.4 Mitral Valve Bioreactor Evaluation:
The final piece to the dynamic model is the proper function of the valve within the
bioreactor. The full mitral valve bioreactor (Figure 3.4 A) can house the mitral valve mount
with the scaffold within and apply the necessary force to condition the valve. Pressure,
heart rate, and stroke volume can be controlled and set at the desired settings using the
specific software. To assess the function of the valve first, the valve must open and close
during the cardiac cycle to allow for the proper flow that would be experienced in the
body. Figure 3.4 B, C shows that the valve is closed during systole and opens during
diastole to allow for the filling of the “ventricle”. The adequate coaptation of the leaflets
can be seen with ultrasound of the valve within the operational bioreactor (Figure 3.4 D,
E, F). The valve showed both leaflets coming together during systole and making a seal.
This prevented regurgitate flow, as demonstrated by the doppler setting in the ultrasound
images. Finally, with a functioning valve and bioreactor, we determined that cells
maintained viability after the week-long conditioning period (Figure 3.4 G, H).
3.5 Conclusion:
A viable MV scaffold was developed and successfully mounted within a fully
functional and tunable bioreactor which showed excellent MV hemodynamics. The
bioreactor was also able to ensure the transport of nutrients and wastes as shown by
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viable cells remaining in the scaffold after one week. With the development of a dynamic
model, further investigations into MV diseases can be explored.
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CHAPTER 4
DETERMINE THE EFFECTS OF HIGH GLUCOSE AND HIGH BLOOD PRESSURE
ON TISSUE-ENGINEERED MVS
4.1 Introduction:
VICs and VECs play a pivotal role in maintaining valve homeostasis and constant
remodeling in the ever-changing environment of the heart. It has been hypothesized that
mechanical stimuli elicit changes in leaflet microstructural composition, thus interfering
with valve mechanics and function [1, 2]. Mechanical stimuli and chemical signals also
moderate the transition of VICs from a quiescent fibroblast to a myofibroblast phenotype
[3-8]. Several studies have shown that inflammatory cytokines, reactive oxygen species,
and the changes in the microenvironment, along with other stimuli, can cause this
transition as well [9, 10]. Diabetes and hypertension are two risk factors that elicit these
biochemical stimuli that can result in the pathogenesis of MV diseases. Diabetes, in
particular, is a significant risk factor for cardiovascular disease [11]. Diabetes leads to the
formation of advanced glycation end products (AGEs). It generates irreversible cross-links
on collagen and elastin along with interference with cellular receptors, leading to a
cascade of reactive oxygen species (ROS) and inflammation formation [11, 12]. It has been
found that inflammation is a critical feature of diabetes. It is not characterized by the
typical signs of inflammation but rather a chronic formation releasing inflammatory
cytokines [13, 14]. These cytokines flow throughout the circulatory system and attach to
and migrate through the endothelial layer, causing responses from native cells such as
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the upregulation of matrix metalloproteinases (MMP) genes [15]. These MMPs are
responsible for the degradation of extracellular matrix (ECM) components. This
degradation of ECM within the MV can result in loss of leaflet mechanical stability and the
billowing or prolapse of the leaflet. The reverse can also be the case. This degradation of
ECM can elicit a mechanical stimulus to the valvular cells to become activated and secrete
more ECM components. Both cases result in pathological remodeling of the MV away
from homeostatic repairs. Along with diabetes and inflammation, there is a reversible risk
factor for MV prolapse: arterial blood pressure [16]. Blood pressure is crucial in
maintaining physiological strain on VICs to maintain homeostasis. Any forces above
physiological, as seen in hypertensive patients, can initiate mechanical activation of the
VICs and ultimately pathological remodeling. Exploring these risk factors in vitro will
provide a vital analysis of MV disease.
4.2 Materials and Methods:
4.2.1 Cellular Seeding:
Decellularized porcine mitral valves were surface and interstitially seeded with isolated
porcine VICs and VECs using a fibrin gel as a medium. Approximately 7 million VICs were
injected using a 28 ½ gauge subdermal needle into each leaflet. Using a transfer pipet, 10
million VECs were drop seeded onto each valve's atrial and ventricular surface. Valves
were placed in the incubator (37 C, 5% CO2, and 95% humidity) to allow for crosslinking
of the fibrin gel. An overnight incubation in a rotator cup at one revolution per min with
DMEM 5% FBS was performed to enable cellular attachment and further gel stability.
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4.2.2 Scaffold Conditioning:
Seven groups (n=3 for each) of cell-seeded scaffolds were created and tested for one
week in either the rotator or bioreactor for conditioning with DMEM, 10% FBS and 1%
ABAM at 37 C in 5% CO2 and 95% humidity. The bioreactor maintained a heart rate of 60
beats per min with a stroke volume maintained at 70 mL. A 3-day ramp-up regime (10
BPM and 20 mmHg) every 12 hours was used to prevent biomechanical shock on the cells.
The valves were monitored with differential pressures and video of valve coaptations to
provide functional analysis of the valves. The six groups are as listed as follows:
•

Group 1: Rotator Control: Valves remained in the rotator cup for a 7-day
incubation at one rev/min.

•

Group 2: Bioreactor Control: Valves were mounted in the MV mount and
subjected to mechanical conditioning in the bioreactor. The bioreactor will be
increased to a normotensive pressure of 120 mmHg systolic and maintained for
four additional days after the ramp-up regime.

•

Group 3: Hypertensive Bioreactor: Valves were mounted in the MV mount and
subjected to mechanical conditioning in the bioreactor. The bioreactor was
increased to moderate hypertensive pressure of 150 mmHg systolic and
maintained for four additional days after the ramp-up.

•

Group 4: High Glucose Rotator: Valves remained in the rotator cup for a 7-day
incubation at one rev/min. 4.5 g/L glucose was added to simulate a
hyperglycemic environment.
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•

Group 5: High Glucose Bioreactor: Valves were mounted in the MV mount and
subjected to mechanical conditioning in the bioreactor. The bioreactor was
increased to a normotensive pressure of 120 mmHg systolic and maintained for
four additional days after the ramp-up. 5.5 g/L glucose was added to simulate a
hyperglycemic environment.

•

Group 6: Hypertensive/ High Glucose Bioreactor: Valves were mounted in the
MV mount and subjected to mechanical conditioning in the bioreactor. The
bioreactor was increased to moderate hypertensive pressure of 150 mmHg
systolic and maintained for four additional days after the ramp-up. 5.5 g/L
glucose was added to simulate a hyperglycemic environment.

4.2.3 Histology and IHC:
Formalin fix and paraffin-embedded tissue samples were sectioned to 5 um,
rehydrated, and stained with hematoxylin and eosin staining for general extracellular
matrix (ECM) compositions and cellular localization. Further ECM composition and
analysis were performed using Masson’s Trichrome combined with Verhoeff-Van Gieson
stain to visualize collagen and elastin within the tissues.
Immunohistochemistry was conducted on 5 um rehydrated samples using
enzymatic antigen retrieval (0.1% proteinase K in TBS), followed by incubation in 0.025
Triton X-100 for 10 minutes. Slides were then subjected to 20 mins of normal block serum
in a humidified chamber at room temperature. Primary antibodies were added to the
slides and incubated overnight at 4 °C in a humidified chamber. Negative controls were
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made by omitting the primary antibody. Secondary antibodies were applied, and the
Vector ABC peroxidase substrate kit and the Vectastain DAB kit (Vector Labs) were used
to visualize the antibody staining. Slides were counterstained using a diluted hematoxylin
solution and then mounted for analysis. Images were obtained at various magnifications
on a Zeiss Axiovert 40CFL microscope using AxioVision Release 4.6.3 digital imaging
software (Carl Zeiss MicroImaging, Inc. Thornwood, NY).
4.2.4 Protein Isolation:
Cells and scaffolds used for western blotting first undergo RIPA buffer extraction.
RIPA buffer contains 50mM Tris-HCl pH 7.4, 150mM sodium chloride, 1mM EDTA, 1%
Triton X-100, 1% Sodium Deoxycholate, 0.1% SDS, with protease inhibitor cocktail in
ddH2O. Cells were washed to remove the excess medium, then incubated in RIPA buffer
on ice for 10 minutes. They were then scraped out of the well with a rubber squeegee,
collected into microcentrifuge tubes, and incubated on ice for 15 minutes, vortexing at
intervals. These samples were centrifuged at 14,000 rcf for 15 minutes to pellet large
proteins. The supernatant was collected and frozen until use. Scaffolds require a few extra
steps. However, the overall procedure was the same. To break down the tissue, tissues
were minced and frozen in liquid nitrogen, then pulverized under a metal rod with a
rubber mallet. These frozen bits of pulverized tissue were collected in a glass tube and
homogenized in RIPA buffer until the solution was homogeneous and lacked noticeable
chunks or solids. The samples were distributed to microcentrifuge tubes and incubated
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on ice while vortexing at intervals; the centrifugation step was run at 14,000 rcf for 15
minutes. The supernatant was collected and frozen until later use.
4.2.5 Protein Quantification and Western Blotting:
Protein concentrations in each sample were measured using the bicinchoninic acid
assay (BCA). This procedure uses albumin as a standard protein concentration, and by
mapping the concentration against the measured absorbance, a line of best fit is made.
Unknown concentrations can then be easily calculated, and optimal volumes for western
blotting were found by calculating the volume in which 20 micrograms are found for each
sample. This volume was mixed with Laemmli’s non-reducing sample buffer to a final
volume of 40 microliters per lane. Protein lysates were then reduced via 2(β)mercaptoethanol and denatured by boiling for 5 minutes. Samples were loaded as desired
and separated via electrophoresis at 100V for approximately 60 minutes. Proteins were
then transferred onto a prepared PVDF membrane; the membranes were blocked for one
hour. Primary antibody solutions (ab34710 collagen type 1, ab5694 α-SMA @ 1:1000)
were applied overnight at 4 °C on a shaker. The following day, membranes were washed
twice in a light detergent buffer and incubated in secondary antibodies for one hour at
room temperature. The membrane was then washed twice and incubated in a detection
solution of luminol and peroxide for 5 minutes before imaging using the Chemi-DocTM
XRS+ system from Bio-Rad (Hercules, CA). Band intensities were determined using BioRad Image Lab Software Version 5.1, beta build 1.
4.2.6 Gelatin Zymography (MMP Analysis):
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During each experiment, media was saved, aliquoted to a small volume, and
frozen at 20°C until ready for gelatin zymography testing. Gels for gelatin zymography
were poured in-house using Bio-Rad equipment. 10% resolving gels were poured and
solidified, and then a 4% stacking gel was poured on top to form the lanes and fingers.
Once this gel solidified, gels were placed in the electrophoresis apparatus and filled with
buffer. Samples were created by diluting media 4x in water, then adding 2x Laemmli’s
sample buffer to the desired final volume. Combs were removed, and equal volumes were
pipetted into each well. For 10-well combs, 40 uL of the sample was used, while for 15well combs, only 25 uL was used. These gels were run at 90V for 90 minutes, then
removed and washed in 2.5% Triton X-100 in PBS to renature the MMPs. The gels were
then transferred to a proprietary development buffer that activates MMPs; they stay at
37°C on a shaker for at least 16 hours until optimal MMP activity has occurred. The gels
are then stained with a Coomassie brilliant blue R-250 staining solution, rendering clear
bands on a dark blue background where the MMPs were active. MMP bands are imaged
using the Chemi DocTM XRS+ system and evaluated using Bio-rad Image Lab Software
with densitometry.
4.2.7 Statistical Analysis:
Results are expressed as Mean ± Standard deviation. Statistical analysis was
performed between groups using Tukey’s student two-tailed T-test in Microsoft Excel.
Statistical significance was determined at a confidence interval of 95% (p<.05).

100

4.3 Results:
4.3.1 Scaffold Preparation and Recellularization:
Decellularized porcine MV was sterilized and then brought to equilibrium with cell
culture media in the incubator before seeding. A thrombin/ cell solution and fibrinogen
solution were created in preparation for the recellularization of the scaffolds (Figure 4.1
A). The two solutions were combined to create a fibrin gel solution that was then added
to the syringe (Figure 4.1 B). 500 uL of fibrin gel with VICs were injected into the anterior
and posterior leaflets (Figure 4.1 C). Additionally, one mL of fibrin gel with VECs was drop
seeded onto the outside of each valve (Figure 4.1 D). Valves were allowed to sit in the
incubator for 20 mins to allow the fibrin gel to solidify before the culture media was
added. All valves were rotated overnight in seeding culture media to allow for initial
cellular attachments.
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Figure 4.1: Mitral Valve Scaffold Recellularization. A) the combination of fibrinogen and
thrombin/cell solutions makes fibrin gel. B) Adding the fibrin gel to the syringe for
interstitial cell seeding. C) Injection seeding VICs into the scaffold. D) Drop seeding VECs
onto the outer surface of the valve. Blue dye was used to visualize seeding coverage.
4.3.2 Macroscopic Observations During In Vitro Conditioning:
During the conditioning of each valve, video documentation of each valve's
performance in the bioreactor was assessed daily from both a top and side view to
assessing proper leaflet coaptation and signs of pathological movements. It was observed
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that all normotensive bioreactors showed no signs of leaflet billowing, indicating prolapse
into the left ventricle (Figure 4.2 A1). However, both the hypertensive (Figure 4.2 A2) and
the hypertensive/ high glucose bioreactor groups (Figure 4.2 A3) showed significant
leaflet billowing into the atrial chamber during systole (Figure 4.2 B).

Figure 4.2: Leaflet Billowing. A) The side view in the bioreactor shows above the atrial
chamber valve. B) Billowing measurements during systole showing significant billowing in
hypertension simulated groups
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After the one-week conditioning period concluded, valves were removed, and
macroscopic images were taken. Both rotator control groups, normal media (Figure 4.3
A) and high glucose media (Figure 4.3 D), had leaflets that appeared thicker in appearance
and more recoiled compared to the bioreactor groups (Figure 4.3 B, C, E, F), which had
thinner more stretched leaflets. It can also be observed in risk factor simulated groups
that there appear to be nodules formed within the leaflets, specifically in the hypertensive
bioreactor group (Figure 4.3 C)

Figure 4.3: Macroscopic Images of Conditioned Mitral Valve. A) Rotator control valve. B)
Normotensive bioreactor valve. C) Hypertensive bioreactor valve. D) High glucose rotator
valve. E) High glucose bioreactor valve. F) Hypertensive/ high glucose bioreactor.
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4.3.3 Mechanical Evaluation of Conditioned Scaffolds:
After each condition was complete, the biaxial protocol was run on the belly
region of each anterior leaflet to evaluate the mechanical properties. Figure 4.4 shows
stress-strain curves for each group's circumferential and radial directions. All
appear to have similar distributions with an initial curved toe region and
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groups

Figure 4.4: Biaxial Stress-Strain Graphs. The blue curve is in the circumferential direction,
and the orange curve is radial direction. A) Rotator control valve. B) Normotensive
bioreactor valve. C) Hypertensive bioreactor valve. D) High glucose rotator valve. E) High
glucose bioreactor valve. F) Hypertensive/ high glucose bioreactor
A later linear portion. The linear part was captured, and the elastic modulus for that
region was calculated (Figure 4.5). There were some significant differences seen, mainly
in the radial direction. Both the high glucose rotator and high glucose bioreactor showed
a significant increase in elastic modulus in the radial direction compared to that of the
rotator control (Figure 4.5)

Figure 4.5: Unidirectional Elastic Modulus Graph. The unidirectional elastic modulus was
found for each sample in each direction. The blue bars are in the circumferential direction,
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and the orange bars are in the radial direction. The colored stars indicated significant
differences between matching colors.
4.3.4 Extracellular Matrix Remodeling:
Histological sections were evaluated after the conditioning of the valves. Figure
4.6 depicts each group's cellular location, migration, and extracellular matrix
modifications. Hematoxylin and eosin staining (Figure 4.6 A1-F2) shows a view of the
leaflet's cross-section and a magnified section of cellular pockets. All conditioned groups
contained cells, and risk factor simulated bioreactor groups (Figure 4.6 C, E, F) showed
signs of loss in matrix integrity. Figure 4.6 A3-F3 shows the combination of trichrome and
VVG staining to visualize elastin and collagen content. Fibrin gel can still be seen within
the scaffolds, as shown by the light red within the stain. Collagen and elastin remained in
the scaffolds but were degraded around cell pockets in risk factor simulated bioreactor
groups (Figure 4.6 C3, E3, F3)
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Figure 4.6: Histological Cross Section of Valve Leaflets. A1-F1) 25 times magnification of
Hematoxylin and eosin staining of valve leaflets showing cellular location along with large-
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scale matrix remodeling in bioreactor groups. A2-F2) 100 times magnification of
hematoxylin and eosin staining of valve leaflets showing cellular pockets and matrix
integrity around those pockets. A3-F3) 200 times magnification of trichrome in
combination with VVG showing collagen (blue) and elastin (black) degradation along with
remaining fibrin gel (red).
4.3.5 Risk Factor Induced Cellular Activation:
The activation of VICs was indicated by the expression of alpha-smooth muscle
actin and calponin via immunofluorescence, along with the increase in MMP activity.
There was an observed increase in expression of aSMA in all interstitially seeded cells of
the risk factor simulated groups compared to normotensive and rotator control groups
(Figure 4.7 A1-F1). The expression of aSMA can also be seen in the endothelial cells
seeded on the scaffolds and is observed more in risk factor simulated groups (Figure 4.7
A2-F2). There was not much expression of calponin observed in any of the samples. This
expression was quantified via western blotting for aSMA (Figure 4.8). There was a higher
expression in risk factor groups, specifically hypertensive and hypertensive/ high glucose
bioreactor conditions.
MMP activity was evaluated using gelatin zymography (Figure 4.9). There was an
increase in MMP activity in the simulated risk factor groups, specifically the hypertensive
and hypertensive/ high glucose conditions.
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Figure 4.7: Immunofluorescence Showing Cellular Activation. A1-F1) aSMA staining of all
sample groups showing an observed higher expression in interstitial seeded cells in the
risk factor simulated groups. A2-F2) aSMA staining of all sample groups showing an
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observed higher expression in the endothelial cells of risk factor simulated groups. A3-F3)
Calponin staining of all sample groups. Very little to no expression was observed except
for the high glucose rotator and bioreactor.

Figure 4.8: Western Blot Analysis of aSMA. The western blot intensities were graphed
for all sample groups in both the anterior and posterior leaflet. While there were no
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significant differences except in one of the posterior leaflets indicated by the green star,
risk factor simulated groups showed an increase in aSMA expression.

Figure 4.9: MMP Activity with Gelatin Zymography. The intensities from the gelatin
zymography were graphed for all samples in both the anterior and posterior leaflets.
There were significant differences seen as indicated by the colored stars with an increase
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in intensities for the risk factor groups specifically the hypertensive/ high glucose
bioreactor
4.3.6 Calcification Evaluation of Conditioned Scaffolds
Calcification of scaffolds and osteoblastic differentiation of cells was evaluated on
each scaffold using histological analysis. Alizarin red staining (Figure 4.10 A1-F2) shows
calcium deposits as brownish-red to bright red. It can be observed that there is some
cellular calcification seen in risk factor simulated groups (Figure 4.10 C1-F2) specifically
the hypertensive and hypertensive/ high glucose conditions. Cellular differentiation was
shown via osteocalcin immunofluorescence staining. While expression was not vastly
seen, it was observed in some of the conditions (Figure 4.10 C3, D3)
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Figure 4.10: Calcification Assessment of Scaffolds. A1-F1) 100 times magnification of
alizarin red staining with reddish-brown to red indicating calcium deposits. A2-F2) 200
times magnification of alizarin red staining with reddish-brown to red showing calcium
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deposits. Small calcification deposits can be seen around cells and cell pockets in risk
factor groups. A3-F3) Osteocalcin immunofluorescence staining showing some expression
in the high glucose rotator and hypertensive bioreactor.
4.3.7 Endothelial Cell Dysfunction:
Endothelial cell function was evaluated by looking at the immunofluorescence of
VWF, eNOS, and E-selectin (Figure 11). It was observed that all conditions exhibited
endothelial cells with the expression of VWF except for groups with hypertension as the
simulated risk factor (Figure 11 C1, F1). The loss of expression in eNOS was observed in
all risk factor simulated groups (Figure 11 C2-F2), with diminished expression in the
normotensive group (Figure 11 B2). E-selectin was expressed in the hypertensive groups
(Figure 11 C3, F3) and the high glucose rotator group (Figure 11 D3).
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Figure 4.11: Endothelial Cell Evaluation Using Immunofluorescence. A1-F1) VWF in all
sample groups was expressed except for hypertensive groups. A2-F2) eNOS was only
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found to be expressed in the rotator control group, with little to no expression seen in
the other groups. A3-F3) E-selectin staining of all sample groups. It was found mainly to
be expressed in diabetic simulated conditions.
4.4 Discussion:
4.4.1 Scaffold Preparation and Recellularization:
Repopulation of cells within the decellularized scaffold is a crucial step in forming
an in vitro model. Natural-based hydrogel fibrin was used as a carrier for the cells due to
its previous use in other cardiovascular applications, as well as significantly improving the
survivability of cells compared to just cell culture media [17, 18]. Figure 4.1 shows the
execution of the fibrin gel combination, the injecting VICs into the leaflet, and coating of
the outside with VECs. The scaffolds were allowed to sit in the incubator for 20 mins which
allowed for the crosslinking of the fibrinogen and thrombin into a solidified clot. Cell
culture media was added to the scaffold and allowed to rotate overnight. This allowed
the cells to attach to the scaffold before adding mechanical forces that would prevent the
proper attachment.
4.4.2 Macroscopic Observations During In Vitro Conditioning:
During bioreactor conditioning of the scaffolds in both normotensive and risk
factor simulated groups, videos were captured to assess the valve function. In Figure 4.2,
signs of leaflet billowing can be seen in the simulated hypertensive groups. Billowing is a
hallmark sign of MV prolapse and will eventually lead to regurgitation if severe enough.
The high pressures for simulating hypertension are taxing on decellularized tissues due to
the inability to properly remodel and adjust for the increase in mechanical forces with the
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lack of cells. The alterations due to the mechanical forces can be seen in Figure 4.3.
Specifically, leaflets can be seen as elongated and thinner in the bioreactor groups and
more so in the hypertensive groups. With the strenuous cyclic load, the collagen and
elastic fibers are stretched, resulting in this elongated leaflet and thinner leaflet (Figure
4.3 B, C, F) compared to those scaffolds that were not mechanically conditioned in the
bioreactor (Figure 4.3 A, D). This appears to be mitigated in areas where cells are located,
indicated by darker and thicker nodular formations in the bioreactor groups, specifically,
the risk factor simulated bioreactor groups (Figure 4.3 C, E, F).
4.4.3 Mechanical Evaluation of Conditioned Scaffolds:
The degenerative nature of most MV diseases results in enlarged leaflets that are
less stiff and more extensible compared to healthy leaflets [19]. In the case of this
research, decellularized leaflets have already been shown to be mechanically not as stable
as healthy leaflets. With the addition of cells to the scaffold, we expect an increase in
stiffness and greater stiffness with the increased activation of cells within the scaffolds.
Through biaxial testing of these scaffolds (Figure 4.4), we could show similar stress-strain
curves that resemble a nonlinear, anisotropic response characteristic of collagenous
tissues, with the circumferential direction being significantly stiffer and less extensible
than the radial directions [1, 20-23]. The linear portion was then chosen to determine the
elastic modulus of each scaffold (Figure 4.5). There was an increase in elastic modulus in
the groups compared to the rotator control and a significant increase in the radial
direction for the diabetic simulated rotator and bioreactor (Figure 4.5). This could be
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because Diabetes leads to the formation of advanced glycation end products (AGEs) and
generate irreversible cross-links on both collagen and elastin along with interference with
cellular receptors [11, 12]
4.4.4 Extracellular Matrix Remodeling:
Degenerative mitral valve disease (DMVD) affects more than 24 million people
worldwide [24]. This is the primary pathological phenomenon seen in industrialized
nations that causes MVR. DMVD presents itself as enlarged leaflets, both in length and
thickness, dilated annulus, and thicker elongated chordae tendinae [25]. This is due to the
increase in ECM remodeling and accumulation of proteoglycans. Microscopically, leaflet
structure shows drastic changes and disorganization as MMVD progresses. In the fibrosa
of the leaflets, there is a loss of collagen fibers and fiber orientation [25-27]. In the in vitro
model presented, changes in the ECM can be observed microscopically (Figure 4.6).
Cellular pockets were located via hematoxylin and eosin staining (Figure 4.6 A1-F2). Cells
remained in these isolated pockets under rotator conditions but migrated away under
mechanical stimulation from the bioreactors. These areas also observed matrix loss under
bioreactor conditions (Figure 4.6 A1-F2). The fibrin gel used as a carrier for the cells during
seeding remained in areas where cells were located but were diminished due to
degradation by the injected cells (Figure 4.6 A3-F3). Collagen and elastic fibers remained
in the scaffold but were degraded in the bioreactor groups. This is due to the mechanical
and chemical stimuli that have activated cells within the scaffold.
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4.4.5 Risk Factor Induced Cellular Activation:
Mechanical stimuli and chemical signals mitigate the transition of VICs from a
quiescent fibroblast to an activated myofibroblast phenotype [3-8]. This is indicated by
the expression of smooth muscle cell markers, the cytoskeletal protein aSMA, and
calcium-binding protein calponin that assist in the contractibility of those cells. It also
involves the increase in MMP activity that degrades ECM proteins. Risk factors such as
diabetes and hypertension increase ROS, lipotoxicity, and apoptosis caused by the
dysregulated environment, leading to a cascade of differentiation of qVICs to aVICs and
ultimately valvular pathologies [28]. The expression of aSMA was observed to be higher
in cases where these simulated risk factors were present (Figure 4.7 A1-F2 and Figure
4.8). Not only were the VICs within the scaffold expressive of aSMA, but so were the VECs
on the external of the scaffold in the risk factor simulated groups (Figure 4.7 C2-F2). VECs
typically do not express the cytoskeletal protein aSMA, but under pathological conditions
can and will eventually lead to EMT.
Calponin is a calcium-binding protein that assists in the regulation of actin/myosin
interactions. This marker is for mature smooth muscle cells involved in active contractile
motions. It is also used as a marker for myofibroblasts that have begun to have contractile
properties. While the expression was minimal to none in most of the sample groups
(Figure 4.7 A3-F3), this could be since the experiment duration was only a week-long and
did not give the activated cells enough time to develop contractile capabilities.
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4.4.6 Calcification Evaluation of Conditioned Scaffolds:
As mentioned previously, activation of MV cells by either mechanical or
biochemical cues results in the pathological development of MV diseases. Two such risk
factors that have been shown to cause a more rapid progression of MV pathologies,
specifically Mitral Annular Calcification, are DM and HTN [29]. Calcification was not
observed in normotensive groups, but in those with simulated risk factors, tiny calcium
deposits could be observed surrounding some cells (Figure 4.9 A1-F2). Osteocalcin is a
bone-derived protein only secreted by osteoblast and is a factor in many things outside
the bone growth and development [30]. For the case of this study, it was aimed at
targeting the differentiation of seeded cells into an osteoblastic phenotype. Expression of
osteocalcin was not widely observed in the sample groups. Some expression was
observed in the high glucose rotator and hypertensive bioreactor (Figure 4.9 A3-F3).
4.4.7 Endothelial Cell Dysfunction:
The dysfunction of the endothelium is usually the first sign of valvular and vascular
pathologies. VECs are crucially important in the normal valve homeostasis. The mitral
valve experiences thousands of cycles throughout its life and must adapt to the everchanging mechanical forces acting upon them to maintain valve integrity and function
[31, 32]. VECs can do this through several different methods, including cellular
transformation, mechanotransduction, and cellular interactions with neighboring VICs
[33-39]. HTN and DM cause vascular inflammation that increases ROS, endothelial
dysfunction, immune activation, and heightened inflammatory response. This increases
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inflammatory cytokines such as interleukin beta 1 (IL-1b), tumor necrosis factor-alpha
(TNF-a), and growth factors such as transforming growth factor-beta (TGF-b) that all
activate signaling pathways that lead to the activation of valvular cells and initiate
pathological remodeling in the valve [40].
Von Willebrand factor was used to assess that the cells were endothelial cells.
VWF is a glycoprotein crucial in the blood coagulation cascade and stored within
endothelial cells. VWF was expressed in all conditions except those that involved the
simulated risk factor hypertension (Figure 4.11 A1-F1). Hypertension has been shown to
lead to endothelial dysfunction, and the expression of aSMA and VWF may not be present
in these cases. The proactive effect of NO produced by the nitric oxide synthase includes
regulating vascular tone, leukocyte adhesion to endothelial cells, cellular proliferation,
platelet aggregation, bone mass and turnover, renal consumption of oxygen, and
angiogenesis [41]. The presence of eNOS is essential in the proper role of the
endothelium. eNOS expression was little to none in all risk factor simulated groups and
diminished in the normotensive bioreactor group (Figure 4.11 A2-F2). The added
mechanical and chemical stress on the cells and lack of communication with neighboring
cells could cause this. The final evaluation of endothelial function was looking at the
leukocyte adhesion molecule expressed on activated endothelium in times of
inflammation to allow inflammatory cells to adhere and enter the tissue from the
bloodstream. E-selectin was expressed in both groups that used high glucose to stimulate
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DM. This is important because DM is known to elicit a chronic inflammatory response in
the body.
4.5 Conclusion:
It was found that with the addition of the simulated risk factors hypertension and
diabetes, pathological responses were observed. Cellular activation was indicated by the
expression of myofibroblast markers, endothelial cell activation markers, and increased
MMP activity. DM and HTN have been shown to cause endothelial dysfunction and were
shown to be the case for groups that simulated these risk factors. Thus, we showed that
the bioreactor model preserves MV function and cell quiescence in physiological
conditions and can also accurately replicate the pathological response of MV to diabetes
and hypertension. To our knowledge, this is the first time that MV disease could be
replicated in vitro including leaflet billowing, matrix remodeling, cell activation and
calcification.
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CHAPTER FIVE
COMPARATIVE IN VITRO AND IN VIVO MODELS OF MV PATHOLOGY: THE
CELLULAR AND MOLECULAR ALTERATIONS ASSOCIATED WITH MV
PATHOLOGY UNDER DIABETIC CONDITIONS
5.1 Introduction:
The prevalence of diabetes (DM) is continuing to rise worldwide. Specifically, type
2 DM currently affects 415 million people and is expected to more than double that in the
next 20 years [1, 2]. DM comes with an elevated risk of getting some form of heart
disease. It was found that among diabetes-related deaths, 68% have heart disease [3].
Several mechanisms initiate complications that stem from chronic hyperglycemia and
insulin resistance. Pathological complications can arise from increased AGEs, oxidative
stress, and inflammation [1, 4]. In the MV, these tend to give rise to activated cells and
pathological remodeling of the valve. MV annular calcification (MAC) is a common finding
in those with DM. The calcification of other valvular components frequently accompanies
MAC as it has been shown to extend into the left ventricle, leaflets, papillary muscles, and
chordae tendinae [5, 6]. MAC and atherosclerosis share similar pathogenesis and risk
factors such as DM. DM has been shown to induce micro-injuries, endothelial dysfunction,
inflammatory cell infiltration, and apoptosis [7]. While similar in endothelial cell
dysfunction and activation, the myofibroblast is the activated form of VICs within the MV
compared to smooth muscle in atherosclerotic blood vessels.
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To validate our in vitro model for examining how risk factors affect MV using a
tissue-engineered approach, this aim utilizes an in vivo diabetic model in minipigs. The
in vivo diabetic model will explore the molecular alterations compared to fresh porcine
valves. We will compare the in vivo diabetic minipig results with those obtained in the
high glucose bioreactor studies (Chapter 4) to better understand basic mechanisms and
provide validation for the in vitro model.
5.2 Materials and Methods:
5.2.1 Diabetic Minipig Model:
Yucatan minipigs (n=6) were rendered diabetic using alloxan infusion at Sinclair
Biologic Inc. and shipped to Clemson. Minipigs were treated with insulin to maintain a
glycemia of around 500 mg/dL and promote weight gain; swine were maintained for ten
months before their euthanasia and tissue collection. Mitral valves were collected for use
in histological and protein analysis.
5.2.2 Cellular Seeding:
As described before (Chapter 4) decellularized porcine mitral valves were surface
and interstitially seeded with isolated porcine VICs and VECs using a fibrin gel as a
medium. Approximately 7 million VICs were injected using a 28 ½ gauge subdermal
needle into each leaflet. Using a transfer pipet, 10 million VECs were drop seeded onto
each valve's atrial and ventricular surface. Valves were placed in the incubator (37oC, 5%
CO2, and 95% humidity) to allow for crosslinking of the fibrin gel. An overnight
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incubation in a rotator cup at one revolution per min with DMEM 5% FBS was
performed to enable cellular attachment and further gel stability.
5.2.3 Scaffold Conditioning:
Three cell-seeded scaffolds were created and tested for one week in the bioreactor
for conditioning with DMEM, 10% FBS, and 1% ABAM at 37 C in 5% CO2 and 95% humidity.
The bioreactor maintained a heart rate of 60 beats per min with a stroke volume
maintained at 70 mL. A 3-day ramp-up regime (10 BPM and 20 mmHg) every 12 hours
was used to prevent biomechanical shock on the cells.
•

High Glucose Bioreactor: Valves were mounted in the MV mount and subjected
to mechanical conditioning in the bioreactor. The bioreactor was increased to a
normotensive pressure of 120 mmHg systolic and maintained for four additional
days after the ramp-up. 5.5 g/L glucose was added to simulate a hyperglycemic
environment.

5.2.4 Histology and IHC:
Formalin fixed and paraffin-embedded tissue samples were sectioned to 5 um,
rehydrated, and stained with hematoxylin and eosin staining for general extracellular
matrix (ECM) compositions and cellular localization. Further ECM composition and
analysis were performed using Masson’s Trichrome combined with Verhoeff-Van Gieson
stain to visualize collagen and elastin within the tissues. Oil Red O was utilized to stain for
lipid deposits in both the fresh and diabetic minipig samples. Alizarin Red was used to
stain for calcium deposits within the tissues.
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Immunohistochemistry (IHC) was conducted on 5 um rehydrated samples using
enzymatic antigen retrieval (0.1% proteinase K in TBS), followed by incubation in 0.025
Triton X-100 for 10 minutes. Slides were then subject to 20 mins of normal block serum
in a humidified chamber at room temperature. Primary antibodies were added to the
slides and incubated overnight at 4 °C in a humidified chamber. Negative controls were
made by omitting the primary antibody. Secondary antibodies were applied, and the
Vector ABC peroxidase substrate kit and the Vectastain DAB kit (Vector Labs) were used
to visualize the antibody staining. Slides were counterstained using a diluted hematoxylin
solution and then mounted for analysis. Images were obtained at various magnifications
on a Zeiss Axiovert 40CFL microscope using AxioVision Release 4.6.3 digital imaging
software (Carl Zeiss MicroImaging, Inc. Thornwood, NY).
5.2.5 Protein Isolation:
Cells and scaffolds used for western blotting first underwent RIPA buffer
extraction. RIPA buffer contains 50mM Tris-HCl pH 7.4, 150mM sodium chloride, 1mM
EDTA, 1% Triton X-100, 1% Sodium Deoxycholate, 0.1% SDS, with protease inhibitor
cocktail in ddH2O. Cells were washed to remove the excess medium, then incubated in
RIPA buffer on ice for 10 minutes. They were then scraped out of the well with a rubber
squeegee, collected into microcentrifuge tubes, and incubated on ice for 15 minutes,
vortexing at intervals. These samples were centrifuged at 14,000 rcf for 15 minutes to
pellet large proteins. The supernatant was collected and frozen until use. Scaffolds
required a few extra steps. However, the overall procedure was the same. To break down
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the tissue, tissues were minced and frozen in liquid nitrogen, then pulverized under a
metal nail with a rubber mallet. These frozen bits of pulverized tissue were collected in a
glass tube and homogenized in RIPA buffer until the solution was homogeneous and
lacked noticeable chunks or solids. The samples were distributed to microcentrifuge tubes
and incubated on ice while vortexing at intervals; the centrifugation step was run at
14,000 rcf for 15 minutes. The supernatant was collected and frozen until later use.
5.2.6 Protein Quantification and Western Blotting:
Protein concentrations in each sample were measured using the bicinchoninic acid
assay (BCA). This procedure uses albumin as a standard protein concentration, and by
mapping the concentration against the measured absorbance, a line of best fit is made.
Unknown concentrations can then be easily calculated, and optimal volumes for western
blotting were found by calculating the volume in which 20 micrograms are found for each
sample. This volume was mixed with Laemmli’s non-reducing sample buffer to a final
volume of 40 microliters per lane. Protein lysates were then reduced via 2(β)mercaptoethanol and denatured by boiling for 5 minutes. Samples were loaded as desired
and separated via electrophoresis at 100V for approximately 60 minutes. Proteins were
then transferred onto a prepared PVDF membrane; the membranes were blocked for one
hour. Primary antibody solutions (ab34710 collagen type 1, ab5694 α-SMA @ 1:1000)
were applied overnight at 4°C on a shaker. The following day, membranes were washed
twice in a light detergent buffer and incubated in secondary antibodies for one hour at
room temperature. The membrane was washed twice and incubated in a detection
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solution of luminol and peroxide for 5 minutes before imaging using the Chemi-DocTM
XRS+ system from Bio-Rad (Hercules, CA). Band intensities were determined using BioRad Image Lab Software Version 5.1, beta build 1.
5.2.7 Gelatin Zymography (MMP Analysis):
During each experiment, media was saved, aliquoted to a small volume, and
frozen at 20°C until ready for gelatin zymography testing. Gels for gelatin zymography
were poured in-house using Bio-Rad equipment. 10% resolving gels were poured and
solidified, and then a 4% stacking gel was poured on top to form the lanes and fingers.
Once this gel solidified, gels were placed in the electrophoresis apparatus and filled with
buffer. Samples were created by diluting media 4x in water, then adding 2x Lamelli’s
sample buffer to the desired final volume. Combs were removed, and equal volumes were
pipetted into each well. For 10-well combs, 40 uL of the sample was used, while for 15well combs, only 25 uL was used. These gels were run at 90V for 90 minutes, then
removed and washed in 2.5% Triton X-100 in PBS to renature the MMPs. The gels were
then transferred to a proprietary development buffer that activates MMPs; they stayed
at 37°C on a shaker for at least 16 hours until optimal MMP activity has occurred. The gels
were then stained with a Coomassie brilliant blue R-250 staining solution, rendering clear
bands on a dark blue background where the MMPs were active. MMP bands were imaged
using the Chemi DocTM XRS+ system and evaluated using Bio-rad Image Lab Software
with densitometry.
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5.2.8 Statistical Analysis:
Results are expressed as Mean ± Standard deviation. Statistical analysis was
performed between groups using Tukey’s student two-tailed T-test in Microsoft Excel.
Statistical significance was determined at a confidence interval of 95% (p<.05).
5.3 Results:
5.3.1 Extracellular Matrix Modification Under Diabetic Conditions:
Histological evaluation was performed on fresh, diabetic minipig, and high glucose
bioreactor leaflets. Figure 5.1 shows cellular locations, densities, and extracellular matrix
composition. Hematoxylin and eosin staining (Figure 5.1 A1-B3) gives a first look at the
cross-sectional comparison between normal, diabetic, and a simulated diabetic model. All
three layers can be seen in the fresh and diabetic minipigs, and these layers are disrupted
within the high glucose bioreactor (Figure 5.1 A3, B3). To further investigate the
composition of the tissues, a Trichrome in combination with VVG was used to look at
collagen (blue) and elastin (black) (Figure 5.1 C1-C3). Collagen and elastin fibers appear
to be intact in all tissues. Still, in the diabetic minipig and high glucose bioreactor, there is
a presence of degradation as indicated by white spaces between the collagen and elastin
fibers (Figure 5.1 D2, D3).
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Figure 5.1: Histological Cross Section of Mitral Valve Leaflets. A) 25 times magnification
of mitral valve leaflets stained with hematoxylin and eosin showing cellular location and
densities in fresh, diabetic minipig, and high glucose bioreactor samples. B) 100 times
magnification of mitral valve leaflets stained with hematoxylin and eosin showing the
cellular location and densities in fresh, diabetic minipig, and high glucose bioreactor
samples. C) 100 times magnification of trichrome in combination with VVG showing
collagen (blue) and elastin (black). D) 200 times magnification of trichrome in
combination with VVG showing collagen (blue) and elastin (black).
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5.3.2 Lipid Infiltration in Diabetic Model:
Oil red O staining was performed on fresh and diabetic minipig frozen sections
(Figure 5.2). There was no observed infiltration of lipids within any of the fresh samples.
A vast amount of lipid deposition was seen in the diabetic minipigs, as indicated by the
bright red deposits in Figure 5.2 A2 and B2.

Figure 5.2: Lipid Deposit in Mitral Valve Leaflets. A) 100 times magnification of an oil
red o staining in fresh and diabetic mitral valves. Diabetic conditions showed prominent
infiltration of lipids via bright red staining. B) 200 times magnification of the same
sample as A.
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5.3.3 Calcification Evaluation of Diabetic Models:
Calcification of the tissues and osteoblastic differentiation of cells was evaluated
on each sample using histological analysis. Alizarin red staining (Figure 5.3 A1, B3) showed
calcium deposits as brownish-red to bright red. It can be observed that there is some
cellular calcification seen in both the diabetic minipig and high glucose bioreactor (Figure
5.3 A2, A3, B2, B3). Cellular differentiation into an osteoblastic state was shown via
osteocalcin immunohistochemistry and immunofluorescence staining (Figure 5.3 C1-C3).
There was a minimal expression for osteocalcin in the fresh samples and the high glucose
bioreactor (Figure 5.3 C1, C3). Osteocalcin expression can be seen in the diabetic minipig
indicated by brown in the histological images (Figure 5.3 C2).
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Figure 5.3: Histological Calcification Evaluation. A) 100 times magnification of alizarin
red staining of the samples. Calcium deposits can be seen by reddish-brown to red
staining in the tissue. B) 200 times magnification of alizarin red staining of the samples.
Calcium deposits can be seen in diabetic minipig and high glucose bioreactor samples. C)
Osteocalcin immunohistochemistry and immunofluorescent. Positive staining is
indicated by brown in C1 and C2 and red fluorescence in C3.
5.3.4 Cellular Activation Due to Diabetic Conditions:
The activation of cells was indicated by the expression of alpha-smooth muscle
actin (aSMA) and calponin via immunofluorescence and immunohistochemistry, along
with the increase in MMP activity. Expression of aSMA was found in both the diabetic
minipig (brown staining) and high glucose bioreactor (red fluorescence), with little to no
expression observed in the fresh tissue samples (Figure 5.4 A1-A3). Calponin can be
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observed throughout the tissue in the diabetic minipig samples (brown staining) but only
observed

Figure 5.4: Histological Analysis of Cellular Activation. A) aSMA staining showing
activated myofibroblast. Diabetic minipigs and high glucose bioreactor show an increase
in expression of aSMA. B) Calponin staining showing mature contractile myofibroblast.
Higher levels of expression can be observed in the diabetic minipig samples.
in isolated areas within the fresh samples (Figure 5.4 B1, B2). Some expression was
observed in the high glucose bioreactor (red fluorescence) (Figure 5.4 B3). Western
blotting analysis showed a significantly higher expression of aSMA in both the anterior
and posterior leaflets of the Diabetic minipig (Figure 5.5).
MMP activity was evaluated using gelatin zymography (Figure 5.6). There was an
increase in MMP activity in the diabetic minipig and high glucose bioreactor compared to
the fresh valve samples.
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Figure 5.5: Western Blot Analysis of aSMA. The intensity of the western blot protein
analysis can be observed in both the anterior and posterior leaflets of the samples. A
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significantly higher expression of aSMA was found in the diabetic minipig for both the
anterior and posterior leaflets.

Figure 5.6: MMP Activity with Gelatin Zymography. The intensities from the gelatin
zymography were graphed for all samples in both the anterior and posterior leaflets.
There were significant differences seen as indicated by the colored stars with an
increase in intensities with the diabetic minipig and high glucose bioreactor.
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5.3.5 Endothelial Cell Dysfunction in Diabetic Models:
Endothelial cell function was evaluated by looking at the immunofluorescence of
VWF, eNOS, and E-selectin (Figure 5.7). It was observed that all samples expressed VWF,
as indicated by the brown staining in the fresh and diabetic minipig images and red
fluorescence in the high glucose bioreactor (Figure 5.7 A1-A3). The loss of expression in
eNOS was observed in the diabetic minipig, as shown by the disruption of brown staining
along the endothelium (Figure 5.7 B2), with little to no expression seen in the high glucose
bioreactor (Figure 5.7 B3). E-selectin was expressed in the diabetic minipig samples
(Figure 5.7 C2).
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Figure 5.7: Endothelial Cell Evaluation. A) VWF immunohistochemistry and
immunofluorescence staining of the samples. All samples were found to be expressing
VWF in their endothelium. B) eNOS immunohistochemistry and immunofluorescence
staining of the samples. eNOS was observed to be expressed in the fresh tissue, with
diminished expression observed in both diabetic minipig and high glucose bioreactor. C)
E-Selectin immunohistochemistry and immunofluorescence staining of the samples. ESelectin was not observed in the fresh sample but was observed in the diabetic minipig
tissues.
5.4 Discussion:
5.3.1 Extracellular Matrix Modification Under Diabetic Conditions:
The mitral valve is composed of three main layers starting from the uppermost
(atrial side) to the bottom (ventricular side) are the atrialis, spongiosa, and ventricularis
[8, 9]. These layers play a crucial role in the function and stability of MV leaflets.
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Alterations to this microstructure can be observed in many MV diseases, especially
myxomatous MV disease (MMVD) which entails enlarged leaflets full of excess
proteoglycans and GAGs, dilated annulus, and elongated chordae frequently engrossed
with calcium deposits. Microscopically, leaflet structure shows drastic changes and
disorganization as MMVD progresses. In the fibrosa of the leaflets, there is a loss of
collagen fibers and fiber orientation [10-12]. DM has been known to accelerate these
modifications seen within the leaflets. Microscopic alteration to the ECM can be observed
in diabetic minipigs and high glucose bioreactor samples (Figure 5.1). The hierarchy of the
leaflet levels that are present within the fresh tissue remains, for the most part, within
the diabetic minipigs. Still, it is vasty disrupted in the high glucose bioreactor. This
disruption can be further visualized by assessing the collagen and elastin content using a
Trichrome combined with VVG staining (Figure 5.1 C1-D3). The diabetic minipig showed
signs of disruption typically isolated in the areas of chordal insertion. The high glucose
bioreactor disrupted and degraded ECM fibers throughout the samples. This is mainly due
to the mechanical instability that decellularized tissues have before being fully
recellularized.
5.3.2 Lipid Infiltration in Diabetic Model:
In diabetic conditions, there is an abnormality in lipid levels that causes adipocyte
hypertrophy. Atherogenic lipid profiles rise and are defined as elevated concentrations of
small dense low-density lipoprotein cholesterol, high triglycerides, triglycerideapolipoprotein B, and usually in combination with low levels of high-density lipoprotein
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cholesterol [13]. This will result in many downstream consequences that lead to the
formation of lipid deposits within cardiac tissues. This can be visualized in the Oil red O
staining that is lipid-soluble and stains lipid and triglyceride deposits bright red (Figure
5.2). In the diabetic minipigs, there is a heavy infiltration of lipids within the valve leaflet.
This was observed to stem from areas of chordal insertion and propagate outwards into
the leaflet. There was no observation of these deposits in the fresh samples. The high
glucose bioreactor could not be stained for lipids due to the lack of frozen tissue samples
to perform the stain on.
5.3.3 Calcification Evaluation of Diabetic Models:
DM is a known contributor to abnormal metabolites and oxidative stress that can
induce different signal pathways that initiate calcification [3, 14]. Calcified deposits can
be observed using alizarin red staining (Figure 5.3 A1, B3). The images observed
calcification in the diabetic minipigs and the high glucose bioreactor, as seen by reddishbrown to red deposits. Osteocalcin is a bone-derived protein only secreted by osteoblast
and is a factor in many things outside the bone growth and development [15]. For the
case of this study, it was aimed at targeting the differentiation of seeded cells into an
osteoblastic phenotype. Expression of osteocalcin was not observed in the fresh tissue or
the high glucose bioreactor (Figure 5.3 C1, C3). There was an expression in the diabetic
minipigs mainly observed around areas with lipid deposits. This is likely because these
areas tend to be high in inflammatory markers, apoptotic cells, and activated
myofibroblast.
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5.3.4 Cellular Activation Due to Diabetic Conditions:
Mechanical stimuli and biochemical signals control the differentiation of VICs from
a quiescent state to an activated myofibroblast form [16-21]. This is indicated by the
expression of smooth muscle cell markers, the cytoskeletal protein aSMA, and calciumbinding protein calponin that assist in the contractibility of those cells. Activated
myofibroblasts also have a higher MMP activity due to the remodeling capabilities of
these activated cells. Diabetes increase ROS, lipotoxicity, and apoptosis caused by the
dysregulated environment, leading to a cascade of differentiation of qVICs to aVICs and
ultimately valvular pathologies [22]. In fresh tissue samples, there was some expression
of aSMA, but this was found to be a minimum and in locations that would be expected to
see them (Figure 5.4 A1). This was typically expressed around arterioles that would
contain smooth muscle cells and occasionally throughout the tissue since the valve is
constantly trying to maintain homeostasis and will cause cells to become activated. The
expression of aSMA actin becomes pathological when the activated VICs cannot revert to
quiescent VICs and remain activated due to surrounding stimuli. A higher level of
expression can be observed in the immunohistochemistry of the diabetic minipig and the
immunofluorescence of the high glucose bioreactor (Figure 5.4 A2, A3). These tissues'
western blot protein analysis showed a significantly increased expression of aSMA in the
anterior and posterior leaflets of the diabetic minipig samples (Figure 5.5).
Calponin is a calcium-binding protein that assists in the regulation of actin/myosin
interactions. This marker is for mature smooth muscle cells involved in active contractile
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motions. It is also used as a marker for myofibroblasts that have begun to have contractile
properties. As mentioned above, there was some calponin expression in the fresh sample,
which is expected in areas containing smooth muscle cells. However, outside of those
regions, this protein should not be expressed. Valvular cells can be seen expressing
calponin in the diabetic minipigs, as depicted by brown staining in the
immunohistochemistry images (Figure 5.4 B2). A slight expression can be seen in the high
glucose bioreactor (Figure 5.4 B3). This expression may be limited due to calponin being
a more mature marker for myofibroblast, and the week-long incubation may not have
allowed for this development.
5.3.5 Endothelial Cell Dysfunction in Diabetic Models:
Patients with diabetes have a high level of glucose and fatty acids in circulation
and are associated with vascular dysfunction through the generation of reactive oxygen
species and inflammation [23]. This can result in endothelial cell injury and dysfunction.
It is characterized as the disruption between vasoconstrictors and vasodilators such as
NO [1]. Along with these functional changes in the valvular endothelium, this
inflammatory condition leads to cell proliferation, remodeling, and apoptosis in the
surrounding tissues. Von Willebrand factor was used to assess that the cells were
endothelial cells. VWF is a glycoprotein crucial in the blood coagulation cascade and
stored within endothelial cells. It is expressed in the fresh, diabetic minipig, and high
glucose bioreactor (Figure 5.7 A1-A3). Reactive oxygen species (ROS) generation in
response to hyperglycemia and the accumulation of by-products such as lipids, proteins,
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and nucleic acids is a crucial mechanism behind the glucotoxicity [24]. With a
dysfunctional endothelium, there is a dysfunction in eNOS, which limits the amount of
the proactive agent NO in the tissues. eNOS expression can be observed within the fresh
valve but is diminished in the diabetic mini pig, as shown by disruption in the positive
brown staining. The presence of eNOS is not observed in the high glucose bioreactor
(Figure 5.7 B1-B3). The final evaluation of endothelial function was looking at the
leukocyte adhesion molecule, E-selectin, expressed on activated endothelium during
inflammation to allow inflammatory cells to adhere and enter the tissue from the
bloodstream. In the environment of glucotoxicity and lipotoxicity, there is an increase in
immune cell infiltration [25, 26]. E-Selectin expression is absent in the fresh samples but
can be observed expressed in the diabetic minipigs (Figure 5.6 C2). This was mainly
observed on the atrial endothelial layer and above the areas of lipid infiltration.
5.5 Conclusion:
The modifications seen in the diabetic minipigs as compared to the high glucose
bioreactor were similar to a degree. Matrix degradation could be observed in some
areas of the diabetic minipig but not as vast as in the high glucose bioreactor. Lipid
infiltration is a hallmark feature in atherosclerosis and is mimicked in other heart
diseases such as MAC. The diabetic minipigs showed this infiltration along with other
atherosclerotic markers such as endothelial dysfunction, activated myofibroblast, and
early signs of calcification. While the high glucose bioreactor was unable to show lipid
deposits, it resembled some critical features of the diabetic minipigs, such as cellular
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activation, endothelial dysfunction, and calcification. Therefore, we showed in this work
that our in vitro model for MV disease could replicate, to an extent, the pathological
cellular and molecular changes seen in the in vivo diabetic model.
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CHAPTER SIX
CONCLUSIONS AND RECOMMENDATIONS FOR FUTURE WORK
6.1 Summary of Project Development:
There is a clear gap in understanding the mechanism behind the risk factors
involved in valvular pathology. Cardiovascular disease (CVD) is a highly prevalent and
ever-growing disease. It is estimated that over 11% of adults have CVD, causing over
600,000 deaths annually and costing an estimated $444 billion [1]. One facet of CVD is
heart valve disease, a significant cause of cardiovascular morbidity and mortality
worldwide that affects more than 1 in 50 people worldwide [2, 3]. Most valve-related
diseases are caused by pathological modifications to the valve or the surrounding tissue
[2]. The mitral valve is the most complex of the heart’s four valves and is most commonly
associated with disease, affecting 2.4% of the population [4-6]. Mitral valve disease has
been linked to various mechanoactive genes, such as extracellular components,
mechanotransductive elements, and transcription factors. Mechanical stimulus in the
microenvironment provides inductive signals of homeostasis and remodeling to the
native cells [4]. Mechanical stimuli and chemical signals thus induce the transition of VICs
from a quiescent fibroblast to a myofibroblast phenotype [7-12]. Diabetes and
hypertension are two risk factors that elicit these biochemical stimuli that can result in
the pathogenesis of MV diseases. Several studies have shown that inflammatory
cytokines, reactive oxygen species, and the changes in the microenvironment, along with
other stimuli, can cause this transition as well [2, 13]. Diabetes, in particular, is a
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significant risk factor for cardiovascular disease [14]. Diabetes affected more than 425
million people in 2017 and is expected to reach over 600 million by 2045 [15].
Hypertension is more prevalent than diabetes and affects an estimated 1.39 billion people
worldwide [1].
Both hypertension and diabetes have been shown to be linked to MV disease, but
the mechanism behind how this happens is not well known. We set to develop a model
that could be utilized to investigate the mechanisms behind valvular pathology and the
risk factors associated with it. Through a tissue-engineering approach using a scaffold,
cells, and bioreactor conditioning, we aimed to create a viable tool that could be used for
further advancements in the field of MV pathology. This model was validated by
comparisons with the analysis of MV obtained from diabetic swine.
6.2 Progress Toward Achievement of Specific Aims:

Aim 1 (Chapter 3): Develop a viable tissue-engineered MV model with bioreactor
conditioning
Hypothesis: MV tissue engineering approaches utilizing scaffolds, cells, and
bioreactors can serve as a reliable in vitro model for studying MV biology and pathology.
Aim 2 (Chapter 4): Determine the effects of high glucose and high blood pressure on
tissue-engineered MVs
Hypothesis: With the addition of diabetes, hypertension, and the combination of
both risk factors during bioreactor conditioning of tissue-engineered MV, we will identify
pathological cellular activation and molecular alterations.
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Aim 3 (Chapter 5): Compare the in vitro and in vivo models of MV pathology: the cellular
and molecular alterations associated with MV pathology under diabetic conditions.
Hypothesis: Alterations of MV VICs and VECs, as well as ECM components by
diabetes, can be identified using MV tissue engineering models and diabetic minipig
models.
6.2.1 Aim 1: Develop a viable tissue-engineered MV model with bioreactor conditioning:
1. A decellularized MV scaffold was developed with the removal of cellular and
nuclear material. Histological analysis and DNA quantification supported this by
showing a significant decrease in cellular and nuclear material to values that are
less than recommended for fully decellularized tissues.
2. We developed a MV mounting mechanism to properly secure the annulus and
papillary muscles in the correct anatomical position in the bioreactor. It also
allowed proper forces to be applied to the chordae tendinae to oppose the
pressure during systole felt by the leaflets.
3. We optimized a fully functioning MV bioreactor to accommodate the valve
mounting apparatus. Bioreactor evaluations showed proper leaflet coaptation
with no regurgitant flow during systole. We also showed the ability to control
settings such as pressure, heart rate, and stroke volume while maintaining cellular
viability during conditioning.
6.2.2 Aim 2: Determine the effects of high glucose and high blood pressure on tissueengineered MVs:
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1. We utilized a fibrin gel as a carrier for porcine VICs and VECs to be seeded on the
MV constructs. The recellularized MV underwent week-long conditioning under
normotensive, high glucose, and hypertensive environments.
2. Macroscopically, we observed that hypertensive environments caused the MV
scaffolds in the bioreactor to exhibit leaflet billowing. This was significantly higher
in hypertensive environments compared to normotensive bioreactors. Postconditioned leaflets in the bioreactor were elongated and thinner compared to
control groups that remained in the rotators with thicker areas in locations of
cellular injections.
3. Our microscopic evaluation showed that cells were located within cellular pockets
in the scaffolds. In bioreactor settings, these cells seemed to migrate and degrade
the surrounding tissue more substantially than those remaining in the rotator
groups.
4. Cellular activation was confirmed in risk factor groups and showed a high
activation level with the expression of aSMA. They also showed more MMP
activity in risk factor groups than in normotensive groups. Calcification was also
demonstrated in risk factor groups, specifically in the hypertensive and
hypertensive/ high glucose groups.
5. Finally, endothelial function was assessed as the beginning stages of many
valvular-related pathologies. We found that DM and HT caused endothelial
dysfunction in both model systems. These results suggest that the bioreactor
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model preserves MV function and cell quiescence in physiological conditions and
can also accurately resemble replicate the pathological response of MV to
diabetes and hypertension
6.2.3 Aim 3: Compare the in vitro and in vivo models of MV pathology: the cellular and
molecular alterations associated with MV pathology under diabetic conditions:
1. We observed several ECM modifications in the diabetic minipig samples, and in
the high glucose bioreactor, compared to fresh tissue. There were voids in the
tissues indicating possible matrix degradation and infiltration of lipids within the
leaflet microstructure in the case of the diabetic minipigs.
2. Calcification of the leaflet tissue was observed in the diabetic minipig models
shown by Alizarin red staining. It was also shown that osteocalcin expression
indicated osteoblastic differentiation in the native cells.
3. Myofibroblast activation was shown to be present in the diabetic minipigs and the
high glucose bioreactor, as indicated from the expression of aSMA in histological
staining. Protein analysis showed a significantly higher expression in the diabetic
minipigs.
4. Endothelial cell dysfunction and activation were shown in the diabetic minipigs.
With diminished eNOS expression and the expression of E-Selectin, the diabetic
minipig endothelium was dysfunctional. This is indicative of typical diabetic
responses seen in other tissues, specifically blood vessels.
6.2.4 Prospective on Progress Made:
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This research has shown that a viable tissue-engineered scaffold can be
developed, recellularized, and conditioned in a custom MV bioreactor that allows for
variable control. Aims 2 and 3 set out to determine if this model could be used to evaluate
hypertension and diabetes. It was shown that the bioreactor could mimic these
conditions and elicit the expected responses due to these risk factors. Compared to an in
vivo model of diabetes with a diabetic minipig, the in vitro model we developed showed
comparable results in critical categories. With only the inclusion of high glucose as our
simulation of diabetes, with further modifications to better resemble a diabetic condition,
such as lipids and the addition of inflammatory cytokines, we could get even closer to this
resemblance of the host response.
The research here showed that we were able to develop a functional mitral valve
model to investigate the mechanism of valvular pathology. This model can be utilized to
investigate many other risk factors and pathologies associated with the MV and possible
treatment options to prevent or halt the progression of MV disease.
6.3 Limitations and Recommendations for Future Work:
6.3.1 Limitations:
While this project showed some progress toward understanding the mechanisms
behind valvular pathology and developing a viable model to study the MV, some
limitations were encountered throughout. Mounting of the scaffolds posed timeconsuming and inconsistent support. The delicate scaffolds against a rigid support system
caused tissue tearing. There was also no control valve with no cells to show how the
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mechanical stresses affected the scaffold itself. The inconsistencies with cellular seeding
lead to a large variance in experimental analysis. Time restraints only allowed for one
week-long bioreactor studies which may have prevented key biomarkers from being
expressed. We conducted 30 bioreactor experiments but several of those were unable to
be analyzed due to bioreactor failures and contamination issues.
6.3.2 Scaffold Seeding and Mounting:
The appropriate scaffold seeding is crucial in the recellularization of these
scaffolds and proper analysis of conditioning groups. Manual injection of cells into the
leaflets of these scaffolds is not a viable method to obtain even cell distribution. Human
error and inconsistent injections of cell volumes result in an uneven distribution of cells
within the leaflets and variable size cell pockets. Additional seeding techniques should be
evaluated to acquire a homogeneous distribution of cells within the scaffold. Along with
the mechanism of seeding, the number of cells injected into the scaffold should be
increased to combat the lack of cells in some areas of the tissue. When analyzing the
current research above, it was sometimes challenging to find cells within and on the
scaffold's outer surface. It also led to variable protein expressions due to insufficient cells
to produce the protein of interest when isolating. The increase in cell number and a more
efficient seeding mechanism will improve in these areas of deficiency.
The mitral valve mount is another route of improvement in the current state of
this project. The existing mount was optimized and performed much better than previous
versions; however, aspects of it still need improving. The annular securement currently
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pinches and “rolls’ The annulus in an upward motion. This is not the typical funnel shape
that it should take. Adding a more flexible interface would allow for better
accommodation of annular shape and mechanics. The papillary muscle securement is
another concern as current method sometimes results in papillary muscle dissection or
chordal rupture. Further work should be made to secure the delicate papillary muscle to
ensure proper tension on the chordae tendinae.
6.3.3 Evaluation of Hypertension and Combination Groups:
While this research was able to show a resemblance between the diabetic
condition in vivo and those produced in the bioreactor, evaluation of the other risk factors
and the combination of risk factors needs to be confirmed. Acquiring an in vivo model for
hypertension at different time points will show if the current in vitro model successfully
elicits pathological responses, similar to those in vivo.
6.3.4 Fresh Mitral Valve Bioreactor Conditioning:
To better understand how the in vitro model produces pathological responses
similar to those seen within the body, a native valve with all native cells and proper ECM
should be evaluated in the bioreactor. Obtaining a fresh native porcine MV and
maintaining sterility and cellular viability should be done. This type of organotypic
experiment has been approached in our lab earlier, but with fresh native aortic valves.
The valve should be properly mounted and secured in the MV mount with chordae
positioned correctly. The valves should then be placed in the bioreactor and conditioned

158

under conditions similar to the research presented above but do not need a ramp-up
period due to the cells in the valve already adjusted to those pressures.
•

Group 1: Rotator Control: Valves will remain in the rotator cup for a 7-day
incubation at one rev/min.

•

Group 2: Bioreactor Control: Valves will be mounted in the MV mount and
subject to mechanical conditioning in the bioreactor. The bioreactor will be
increased to a normotensive pressure of 120 mmHg systolic and maintained for
seven days.

•

Group 3: Hypertensive Bioreactor: Valves will be mounted in the MV mount and
subject to mechanical conditioning in the bioreactor. The bioreactor will be
increased to moderate hypertensive pressure of 150 mmHg systolic and
maintained for seven days.

•

Group 4: High Glucose Rotator: Valves will remain in the rotator cup for a 7-day
incubation at one rev/min. 5.5 g/L glucose will be added to simulate a
hyperglycemic environment.

•

Group 5: High Glucose Bioreactor: Valves will be mounted in the MV mount and
subject to mechanical conditioning in the bioreactor. The bioreactor will be
increased to a normotensive pressure of 120 mmHg systolic and maintained for
seven days. 5.5 g/L glucose will be added to simulate a hyperglycemic
environment.
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•

Group 6: Hypertensive/ High Glucose Bioreactor: Valves will be mounted in the
MV mount and subject to mechanical conditioning in the bioreactor. The
bioreactor will be increased to moderate hypertensive pressure of 150 mmHg
systolic and maintained for seven days. 5.5 g/L glucose will be added to simulate
a hyperglycemic environment.

6.3.5 Variable Time-Point Studies:
The current research only represents a snapshot into the mechanisms of valvular
pathology. To fully understand how MV diseases initiate and progress, variable time
points should be analyzed, starting with a baseline at day zero. Weekly time points should
be evaluated up until disease progression reaches known instances. The cellular
modifications and how each risk factor accelerates disease can then be fully explored.
6.3.6 Control Valve Without Cells
It is important to have a valve that was conditioned in the bioreactor without any
cells to see how the scaffold would react to the mechanical stimuli. This is especially
important in the hypertensive environments where we saw the leaflet billowing. This
would show if the billowing was caused due to the stretching of the mechanically weaker
decellularized scaffolds or from another source when the cells were added.
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